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Characterization of Novel CYP26B1-inhibitor, DX314, for the Treatment of Keratinization
Disorders
Chairperson: Philippe J. Diaz

Our skin, particularly the barrier provided by the epidermis, functions as our primary
protection from the harsh environment. It protects us from dangerous pathogens, allergens,
ultraviolet radiation, and mechanical injury, as well as playing a major role in fluid and
thermal regulation. Disruption of skin functions can lead to life-threatening consequences
due to increased risk of infection, trans-epidermal water loss, and allergen sensitization.
Many common skin disorders often result in a disrupted skin barrier placing patients at risk
of complications.
Retinoic acid (RA) is a major component of the vitamin A pathway, which critically
controls multiple skin functions including cell proliferation and differentiation, barrier
maintenance and immune regulation. Retinoid-based therapies have successfully been used
to treat various skin disorders, such as ichthyosis and Darier’s disease, however, the
prevalence of adverse effects, including dry skin, irritation, redness, photosensitivity, and
barrier dysregulation, can result in complications and poor compliance. Novel, selective,
retinoic acid metabolism blocking agents (RAMBAs), intended to minimize adverse
effects and improve patient outcomes, have been designed and synthesized by our lab.
In these studies, we first investigated whether our novel RAMBA, DX314, can potentiate
the effects of RA, via inhibition of the RA-metabolizing enzyme, CYP26B1, in healthy
human epidermis models. By studying the gene expression effects of RA, DX314, and two
previous-generation RAMBAs (liarozole and talarozole), we show that DX314 does
potentiate the effects of RA. Additionally, by studying its effect on epidermal histology
and transepithelial electrical resistance, we discovered that DX314 displays a unique skin
barrier-reinforcing property. In our second series of studies, we investigated DX314’s
therapeutic potential in Darier’s disease and ichthyosis. These results confirm DX314’s
ability to potentiate RA, and its barrier-reinforcing properties, in diseased skin models and
suggest that DX314 has potential as a novel therapeutic agent for keratinization disorders.
Together, the studies within this dissertation show our next-generation RAMBA, DX314,
is a strong candidate for further drug development in the context of keratinization disorders.
If successful, DX314 could fulfill the therapeutic need for an efficacious, selective
RAMBA, providing improved patient outcomes and quality of life, with greatly reduced
adverse effects relative to current treatment options.
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1. INTRODUCTION
1.1 HUMAN SKIN
Our skin primarily functions as a critical barrier between our internal tissues and
the harsh external environment. It provides protections against pathogens, allergens,
ultraviolet (UV) radiation, mechanical and chemical insults, as well as playing a major role
in fluid regulation and thermal homeostasis. Beyond the protective nature of the skin, it
also provides important sensory (tactile feedback via dermal nerve endings), metabolic
(vitamin D synthesis), and energy storage functions (subcutaneous adipocytes) 1.
Disruption of these critical skin functions, whether by disease pathology or physical
destruction (e.g. severe burns, abrasions), can result in major complications for patients.
These consequences include increased risk of infection, trans-epidermal water loss
(TEWL), and allergen sensitization2–4.

Figure 1.1: Illustration of
primary skin structures.
Including

the

(subcutaneous

hypodermis
fat),

dermis,

epidermis, and other major skin
structures such as sebaceous
glands, hair follicles, and sweat
glands.
Source: Graham-Brown et al.
(2016), with permission from
John Wiley and Sons (lic. #:
4606680766115)
1

1.1.1 ANATOMY OF THE SKIN
Human skin can be divided into three primary layers: the most internal layer is the
hypodermis, the middle layer is the dermis, and the external layer is referred to as the
epidermis (Figure 1.1).

1.1.1.1 HYPODERMIS
The hypodermis, also referred to as subcutaneous tissue, is the innermost layer of
the skin below the dermis and above skeletal muscle. It is primarily composed of
adipocytes, collagen, and blood vessels which together function as thermal insulation,
energy storage, and protection from mechanical trauma5,6. The thickness of this layer is
highly variable across individuals and its specific location.

1.1.1.2 DERMIS
The dermal layer of the skin is localized between the hypodermis and the epidermis,
ranges between 0.3mm (eyelids) and 3mm (back) thick and is primarily composed of
connective tissue. This layer is divided into two regions known as the papillary dermis and
the reticular dermis. The aptly named papillary layer contains dermal papilla, localized just
below the epidermis, which provide resistance to shear stress. The remaining reticular layer
accounts for most of the dermis and provides structural and elastic support. Other structures
found within the dermis include sweat glands, hair follicles, sensory receptors such as
Meissner’s and Pacinian corpuscles, free nerve endings, and sebaceous glands (Figure 1.1).
The primary cell types found within the dermis include fibroblasts, mast cells
(specialized secretory cells), macrophages (phagocytic cells), and various T cells (immune
cells)7. Fibroblasts (the major cell type of the dermis) are responsible for the synthesis of
2

the dermal matrix which consists of approximately 70% collagen with some elastin, as well
as a mucopolysaccharide gel which fills the inter-fibrous spaces and functions as a hydrogel
to facilitate diffusion of fluids, nutrients, and other essential components. The highly
diverse fibroblast populations within the dermis also produce several growth factors (e.g.
keratinocyte growth factor (KGF), hepatic growth factor) as well as many cytokines (e.g.
interleukins (IL)-1α/β, IL-8).
The dermis is highly innervated, which allows for its role in pain, itching, and tactile
sensations. A critical function of the dermis is to support the epidermis by providing
essential nutrients. Due to the lack of blood supply to the epidermis, the richly vascularized
dermis provides a supply of nutrients and oxygen to the epidermis via diffusion 1,5,6,8.

1.1.1.3 EPIDERMIS
The exterior layer of the skin is the epidermis [epi- (on top of, Ancient Greek) the
dermis] which functions as our foremost barrier between internal tissues and the
environment. The epidermis is composed of a stratified squamous epithelium composed of
several distinct layers. Thick skin (found on palmar and plantar surfaces) has an epidermal
thickness of 0.8-1.5mm, while thin skin (majority of our skin) has an epidermal thickness
ranging from 0.07-0.15mm1.
The primary cell type found in the epidermis are keratinocytes (constituting >90%
of the epidermal cell population1) which undergo carefully controlled differentiation to
form the stratified epithelium of the epidermis. The four layers of the epidermis from the
most internal to the most external are; the stratum basale (SB, basal layer), stratum
spinosum (SS, spinous layer), stratum granulosum (SG, granular layer), and the stratum
3

corneum (SC, corneal layer) (Figure 1.2). Melanocyte cells, also found within the
epidermis, are responsible for production of melanosomes, which contain the dark pigment
melanin. Melanin provides essential protection from UV radiation by absorbing harmful
high energy photons and preventing them from causing permanent damage to cellular
DNA. Langerhans cells are antigen-presenting cells, originating from monocytes, which
provide immunologic defense within the skin 1,5,6,8.

Spinous Layer

Figure 1.2: The human epidermis. Human skin section (left) showing dermal
collagen (yellow) and epidermal keratinocytes (pink/purple), merged with an
illustration of the epidermis (right). The four distinct layers of the epidermis
(basal, spinous, granular, and corneal) can be seen in both images.
Adapted from: left, Frankart et al. (2012); right, Graham-Brown et al. (2016),
with permission from John Wiley and Sons (lic. #: 4606620180670,
4606611448338)
1.1.1.3.1 EPIDERMAL STRATIFICATION
Stratification and maintenance of the epidermis is the result of a careful regulation
of keratinocyte differentiation and proliferation. Proliferating keratinocytes originate from
4

keratinocyte stem cells found in the basal layer of the epidermis. As these keratinocytes
undergo the process of terminal differentiation, they migrate upwards to sequentially form
the suprabasal layers. Each of these layers have unique, critical characteristics and
morphologies (Figure 1.3). In vivo, the differentiation process from basal to corneal
keratinocytes is estimated to take approximately 14 days, where they remain for about
another 14 days as corneocytes before subsequent desquamation (shedding of the
outermost layer). The total skin rejuvenation cycle takes around 28 days 5,6,8,9.
1.1.1.3.2 STRATUM BASALE
The basal layer, also called the stratum basale, is the innermost layer of the
epidermis found directly above the dermis. This layer is composed of 1-3 layers of
undifferentiated, cuboidal keratinocytes which can either replenish basal cell populations,
or undergo terminal differentiation. Melanocytes, which produce the UV-absorbing
melanosomes, are also found within this layer and account for 5-10% of basal cells.

Figure

1.3:

Epidermal

keratinocyte

differentiation. Each layer of the epidermis has
unique properties and expression patterns related
to the state of keratinocyte differentiation (left).
Relative calcium and pH gradients in each layer,
which play an important role in differentiation
and desquamation, respectively (right).
Adapted from: Eckhart et al. (2013), with
permission

from

Elsevier

(lic.

#:

4606630114712)
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[Ca2+]

pH

Basal stem cell populations are responsible for maintaining epidermal homeostasis.
Several hypothesis on the mechanisms of this are available, however, the currently favored
of them suggests a combination of symmetric and asymmetric cell division 10–13. This
hypothesis states that stem cells can either self-renew (symmetric), differentiate
(symmetric), or asymmetrically divide, to maintain stem cell populations while generating
differentiating keratinocytes for the suprabasal layers (Figure 1.4).

Figure 1.4: Cell division of basal keratinocytes. Representation of
symmetric and asymmetric cell division thought to be the mechanisms
responsible for epidermal maintenance by basal keratinocytes.
Adapted from: Simpson at al. (2011), with permission from Springer Nature
(lic. #: 4606630776515)
The extracellular matrix (ECM) interface separating the basal epidermis from the
underlying dermis is known as the basement membrane zone. Polarized basal keratinocytes
produce intracellular intermediate filaments (keratins 5 and 14), which provide an anchor
for integrin complexes (hemidesmosomes). These hemidesmosomes provide the necessary
attachment to the laminin- and collagen-containing basement membrane5,13,14. Proper

6

attachment at the dermal-epidermal junction is mechanistically complex, but essential to
the skin’s ability to provide a functional barrier.
1.1.1.3.3 STRATUM SPINOSUM
Just above the stratum basale lies the 8-10 cell deep1 stratum spinosum (spinal
layer) of the epidermis. Once basal keratinocytes have been committed to terminal
differentiation, they lose their columnar appearance and become increasingly polygonal as
they form the spinal layer.
In addition to keratinocytes, 2-8% of the cells within the spinous layer are dendritic
Langerhans cells1. Langerhans cells are monocyte-derived, antigen-presenting cells
originating from bone marrow, which play a critical role in the immunologic functions of
the skin. Once an antigen has been captured, Langerhans cells may migrate to the peripheral
lymph nodes to present it to the appropriate T cell, or activate resident T cells within the
epidermis15, to initialize the required immunologic response16.
The name of this layer originates from the appearance of spinous keratinocytes
when stained with hematoxylin and eosin (HE) dyes and viewed under a microscope. The
staining process causes the cells to shrink, while the cadherin-based desmosomes keep the
cells bound to each other, resulting in “spines” forming at each interface. Desmosomes,
tethered by intracellular keratin filaments, are intercellular connections between
keratinocytes forming strong, shear-resistant bonds within the tissue.
As keratinocytes integrate into the spinous layer, genes for the fibrous protein
keratins (KRT) found in proliferating basal keratinocytes (KRT5 and KRT14) are turned
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off, and expression of KRT1 and KRT10 takes over. For this reason, KRT1 and KRT10
gene expression is often used as a marker of keratinocyte differentiation 13,14.
1.1.1.3.4 STRATUM GRANULOSUM
The next stage of differentiation forms the 3-5 cell thick granular layer, named after
the dark-staining keratohyalin granules (KG) found within the keratinocytes of this layer.
Keratohyalin granules contain pro-filaggrin which undergoes proteolysis to become to the
keratin-aggregating protein filaggrin (FLG). These aggregated keratins make up a flexible
matrix which also contains involucrin (IVL) and loricrin (LOR). IVL and LOR are
structural proteins which play an important role in the cornification process needed to
create to the stratum corneum5,9,17.
The stratum granulosum is the primary location of epidermal tight junctions (TJ,
can also be found in hair follicles18) which are critical barrier components responsible for
controlling paracellular fluid and ion diffusion, and protecting against pathogen
penetration. Tight junctions are composed of intercellular claudins (CLDN), occludin
(OCLN), and junctional adhesion molecules (JAM), scaffolded to intracellular zonula
occludens (ZO) proteins linked to the cell’s actin cytoskeleton (Figure 1.5) 13,19–21.
The careful regulation of calcium ions in the epidermis plays a major role in
regulating keratinocyte differentiation. A calcium gradient, with the highest concentrations
found in the stratum granulosum and concentrations decreasing both above and below, is
tightly controlled to maintain proper function22 (Figure 1.3). Elevated calcium levels
activates enzymes in the protein kinase C (PKC) family which will downregulate KRT1
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and KRT10, while upregulating IVL, LOR, and transglutaminases (TGM) 23 expression,
which in addition to FLG, are used as markers of late keratinocyte differentiation.

Figure 1.5: Structure of tight junctions found in the stratum granulosum. Tight
junctions play an important role in skin barrier function by preventing paracellular
diffusion through the granular layer of the epidermis.
Source: Simpson at al. (2011), with permission from Springer Nature (lic. #:
4606631204611)
Morphologically, granular keratinocytes undergo a characteristic flattening and
observable degradation of their nuclei and organelles. Lipid- and hydrolase-secreting
lamellar bodies being to form and produce an extracellular “mortar” at the granularcornified transition24. The drastic changes seen in the granular layer prepare the
keratinocytes for their final transition into the stratum corneum by a process known as
cornification.
1.1.1.3.5 CORNIFICATION AND THE STRATUM CORNEUM
The outermost layer of skin, and terminal destination for keratinocytes, is the
stratum corneum, also referred to as the corneal layer. In a process that began in the
granular layer, keratinocytes undergo a distinct type of programmed cell death called
cornification. The nucleus and other organelles (i.e. mitochondria, Golgi apparatus,
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ribosomes, endoplasmic reticulum) are degraded and replaced by structural proteins and
other corneal layer components.
FLG, formed within the granular keratinocytes, aggregate keratin filaments which
causes the keratinocytes to collapse into organized sheets of flattened polyhedral cells
named corneocytes. Proteins such as IVL, LOR, trichohyalin (TCHH), and small prolinerich proteins (SPR) are expressed and cross-linked by TGMs to form a cornified envelope
(CE) on the cytoplasmic side of the cell membrane. The CE of each corneocyte is linked
to neighboring CEs via modified desmosomes, referred to as corneodesmosomes, to form
tight bonds within the stratum corneum. Lamellar bodies secrete their lipid- and enzymerich contents (e.g. ceramides, sterols, phospholipids) which function as a “mortar” between
the layers of protein-rich corneocyte “bricks” (Figure 1.6)9,17,25.

Figure 1.6: Lamellar body secretion during the formation of the
stratum corneum. Lamellar bodies originating in the stratum granulosum
release lipids and enzymes, which play critical roles in barrier function, into
the stratum corneum where they act as an inter-corneocyte “mortar”.
Adapted from: Proksch et al. (2008), with permission from John Wiley and
Sons (lic. #: 4606641010025)
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The stratum corneum is highly variable in thickness depending on location and can
be anywhere from 15 (upper arm) to hundreds (palms and soles) of layers thick 1.
Considering the thick and tightly bound, hydrophobic makeup of the corneal layer, it is no
surprise that it also plays a major role in skin barrier function.
As epidermal tissue is constantly being rejuvenated, a mechanism to make way for
new tissue is necessary. The process of desquamation refers to the controlled shedding of
corneocytes from the outermost layers of the stratum corneum. As corneocytes migrate
from the deeper, denser corneal layers (stratum compactum) to the upper corneal layers
(stratum disjunctum), they undergo compositional changes which promote desquamation 6.
One such change is a shift in the equilibrium of proteases and protease inhibitors, which
allows for proteolysis of corneodesmosomes and shedding of those corneocytes. This
balance is thought to be controlled by the pH gradient found in the corneal layer. The
stratum compactum maintains a fairly neutral pH, ideal for protease and inhibitor function,
however, the stratum disjunctum is markedly more acidic (pH 4-6) 26,27, which reduces
protease inhibitor effectiveness28. (Figure 1.3) Although protease function is also decreased
by the low pH, they are less effected than protease inhibitors, so the resulting desquamation
is gradual and well controlled.

1.1.1.4 SKIN BARRIER FUNCTION
As previously discussed, the major function of the epidermis is maintaining a
proper barrier between internal tissues and the external environment. The barrier can be
divided into two major categories; the inside-outside barrier, consisting of fluid, ion, and
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thermal homeostatic mechanisms, and the outside-inside barrier, protecting internal tissues
from pathogens, allergens, UV radiation, mechanical, and chemical insults.
As the outermost layer, the stratum corneum is the skin barrier’s first line-ofdefense. The tightly bound layers of corneocytes and extracellular lipids provide a
hydrophobic and difficult to penetrate barrier which contributes to both inside-outside
(fluid regulation), and outside-inside (penetration) protections. The SC also contains
antimicrobial peptides (AMPs), cytokines, antioxidants, and many other components that
provide additional protections essential to the barrier function (see Section 1.1.1.3.5).
In addition to regulating desquamation, the previously mentioned acidic
environment of the skin surface aids in processing barrier lipids and discourages
pathogenic bacteria proliferation in favor of the normal skin flora 26.
Tight junctions found on the apical side of keratinocytes in the stratum granulosum
are another significant component of the epidermal barrier. These cell-cell junctions tightly
bind keratinocytes together forming a paracellular barrier not only to xenobiotics and
pathogens, but also passively regulating bi-directional fluid and ion permeability29 (see
Section 1.1.1.3.4).
The pathogen-directed skin barrier components are the first line of defense
protecting our internal tissues from infection. The presence of a healthy skin microflora
has recently gotten more recognition as an important exogenous component of the skin
barrier. By outcompeting pathogenic microbes on the surface of the skin our microflora
decreases our risk of infection30. Keratinocytes also produce antimicrobial peptides
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(AMPs, e.g. β-defensins and cathelicidins), delivered from lamellar bodies, which protect
against bacteria, viruses, parasites, and fungi31. Finally, if an antigen gets past these initial
protections, whether through barrier deficiency or physical injury, it is the role of spinous,
antigen-presenting Langerhans cells to activate an immunological response (see Section
1.1.1.3.3).
Epidermal cytokines released by keratinocytes also play a role in maintaining the
skin barrier by activating signaling cascades in response to insults. Cytokines such as IL1α/β, tumor necrosis factor (TNF)α, IL-17α, IL-34, IL-24, and others, will activate the
repair process of damaged tissue and induce a pro-inflammatory signal 30,32,33.
The interaction between individual components contributing to the homeostatic
mechanisms which maintain the barrier are important to consider as well. Studies have
found that the corneal barrier and granular tight junctions will compensate for decreased
function of the other (e.g. increase in TJs when corneum is disrupted34 or a denser, thicker
corneum in claudin-1 deficient mice35). Studies have also found interactions between the
immune barrier and the corneal and granular barriers being able to compensate for, or
activate, when the other is deficient32,36–38.
1.1.1.4.1 MEASURES OF EPIDERMAL BARRIER FUNCTION
There exist several established methods to assess epidermal barrier function, both
in vitro and in vivo, which allow researchers and physicians to quantify changes in barrier
function.
Transepithelial electrical resistance (TEER) is a common, non-destructive
methodology used to measure barrier function in vitro. It functions by placing an electrode
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above and below a tissue immersed in culture media (Figure 1.7) acting as an electrolyte,
and applying a weak alternating current (10µA) which allows for a measure of electrical
resistance (ohm, Ω) across the tissue. By subtracting out the resistance of an empty cell
culture insert, the specific resistance of the tissue itself can be determined. This resistance
is directly related to the freedom of ion to flow through the tissue via paracellular
(controlled by tight junctions) and transcellular pathways. A decrease in TEER corresponds
to decreased resistance to ion permeability across the tissue, and therefore a weaker
epithelial barrier.

Figure 1.7: Illustration of TEER
electrode placed in measurement
position. Using electrode placed on
either side of a tissue submerged in
culture media, we can determine the
electrical resistance across the tissue
as measure of tissue barrier integrity.

Trans-epidermal water loss (TEWL) is another non-invasive measure of barrier
integrity which, unlike TEER, can be used both in vivo39 and in vitro40. As implied, TEWL
is a measure of the passive diffusion of water across the epidermis, which is directly related
the skin’s inside-outside barrier function. The TEWL instrument used in these studies
(Biox Aquaflux AF200) utilizes a sealed condenser chamber, which is placed over the
tissue in an airtight manner (Figure 1.8). The chamber contains a chilled (-7.65°C)
condenser plate to control the humidity within the chamber, as well as relative humidity
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and temperature sensors between the condenser and the epidermis. As water vapor diffuses
from the tissue surface to the condenser, the sensors calculate water vapor flux over time.
To correct for the initial skin surface water loss (SSWL), which could contaminate the data,
TEWL is measured over a period of 60-90s and once a steady state threshold has been
achieved the water flux is recorded as mass of water per area over time (typically g/m 2h).
Although TEWL is a useful tool to measure barrier integrity, it is inherently sensitive to
subtle external influences. Care must be taken to maintain constant ambient humidity and
temperature and ensure the surface of the tissue is thoroughly dried before measurement.

Figure

1.8:

Illustration

of

TEWL measurement device on
reconstructed epidermis. An
evaporimeter measures water flux
through the tissue. TEWL is used
in vivo, or in vitro (shown here),
to assess skin barrier integrity
based on water permeability.

Other methods to measure barrier function include chemical permeation assays. A
low-binding, low-molecular weight chemical can be applied to the surface of the tissue and
the amount that is able to permeate into the media below can be quantified. Fluorescent
dyes are commonly used for this type of assay and can also be used to visualize dye
penetration by fluorescent microscopy of tissue cross-sections. A downside is this type of
assay is the invasive nature of chemical treatments, which may affect the tissue in
unpredictable ways. These assays are typically performed in independent, single-use
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studies, whereas TEER or TEWL can be measured multiple times at several stages of tissue
growth, or at various treatment times, in most studies without interfering with other
downstream assays.

1.2 DISEASES OF THE SKIN
Since the skin plays such a major and critical role in protecting us from the insults
of our environment, it is no surprise that skin diseases can have a devastating effect on
patient health and quality of life. As previously discussed, maintaining healthy skin
involves a series of carefully regulated, complex biological process for proper function.
Even seemingly minor perturbations of many of these processes can result in severe disease
states requiring medical intervention. Untreated skin diseases can result in increased
infection risk, severe irritation, allergen sensitization, dehydration, vitamin D deficiency,
thermal dysregulation, UV-damage, and psychological distress 8.

1.2.1 CONGENITAL ICHTHYOSIS
Congenital ichthyoses are a group of hereditary keratinization disorders.
Keratinization is the process of keratinocyte differentiation, referring to the formation of
keratin filaments. Originally derived from the Greek word for fish (“ichthys”), ichthyosis
can cause skin to resemble fish scales due to improper cornification (Figure 1.12a 41).
Congenital ichthyosis covers a wide gamut of related disorders and as such, there
are many possible genetic causes attributed to the disease (Table 1.1 42). Some forms, such
as ichthyosis vulgaris and recessive x-linked ichthyosis (RXLI), are more common (1/300
and 1/2,500 respectively), while others, such as lamellar ichthyosis (LI) and bullous
ichthyosis, are fairly uncommon (1/100,000 and 1/300,000 respectively) 43. Severity is also
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highly variable with less severe forms, such as ichthyosis vulgaris, having low mortality,
while other forms, such as harlequin ichthyosis, resulting in neonatal survivability as low
as 56%44. Symptoms can include dry skin (xerosis), redness and irritation (erythema),
scaling and blisters, abnormal thickening of the skin (hyperkeratosis), and other
problematic conditions43.

Table 1.1: Major types of congenital
ichthyosis by culprit gene. Ichthyosis
can be caused by many different genetic
components. A disruption in any of the
critical factors involved in the complex
process of keratinization can result in
dysfunction and medical complications.
Source: Online Mendelian Inheritance
in Man (OMIM, https://omim.org).

Current treatment options for these disorders typically target a combination of three
strategies; hydration, lubrication, and keratolysis43. The two former strategies focus on
mitigating symptoms, while the latter (often via retinoid treatment) targets the underlying
biological mechanisms the diseases. Retinoid-related treatments (further discussed in
Section 1.3) function as keratolytics and reduce hyperkeratosis, keratinocyte
hyperproliferation, and excessive corneocyte production. Unfortunately, this treatment
mechanism can result in adverse effects, including additional barrier dysfunction, and often
require additional treatment with antimicrobials.
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1.2.2 DARIER’S DISEASE
Darier’s disease (DD, keratosis follicularis) is a rare (between 1 in 36,000 and 1 in
100,00045), autosomal dominant skin disorder characterized by disrupted intercellular
adhesion (acantholysis) and abnormal keratinization (dyskeratosis). DD is caused by a
mutation in the ATP2A2 gene which encodes a calcium transporter (SERCA2) 46 found in
the endoplasmic reticulum of keratinocytes. Due to the importance of calcium ion gradients
in skin development, epidermal homeostasis is consequently disrupted in DD. This results
in abnormal keratinocyte differentiation, poor intercellular adhesion, and dark, crusty skin
lesions, which together cause severe itching, pain, and increased risk of infection.
DD is treated similarly to other keratinization disorders; emollients and
corticosteroids to address irritation, retinoids to control dyskeratosis 47–49, and antibiotics
which may be used during flare ups. Retinoids such as isotretinoin (13-cis-retinoic acid),
adapalene, tazarotene, acitretin, and others, have been used in the treatment of DD via
topical and oral formulations45,47,49,50.

1.2.3 ATOPIC DERMATITIS
Atopic dermatitis (AD) is a common chronic inflammatory skin disease (affects 1530% of children and 2-10% of adults) with recently increasing prevalence 51. AD patients
present with xerosis, itching (pruritus), lesions of erythema which increase the risk of
infection, and atopy (a genetic tendency to develop allergen sensitization) 52. Since there
are no specific markers for AD, diagnosis can be difficult and is typically done by looking
for a defined set of clinical manifestations53, including early onset age and the symptoms
previously mentioned.
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Noted features of AD are barrier dysfunction, measured by increased TEWL,
inflammation, and immune dysfunction. It is currently unknown if one may lead to the
other, but it is clear they are closely linked to each other and both genetic and
environmental factors contribute to AD54,55. Mutations in barrier proteins, such as FLG and
SPINK5, as well as immune factors such as IL- 4 & 13, toll-like receptor 2 (TLR2) and
others have been associated with AD56,57.
Like congenital ichthyosis, current AD treatment options are limited and often
target symptoms rather than the underlying causes. Moisturizers and emollients hydrate the
skin and mitigate TEWL, cortical steroids and calcineurin inhibitors target inflammation,
and in severe cases, immunosuppressants are also used. Finally, ceramide and lipid-based
formulations can be used to partially restore some barrier function lost in AD.

1.2.4 OTHER SKIN DISEASES
There exists such a wide gamut of different skin diseases that discussing the field
of dermatology in its entirety is not feasible in this summary. This section will provide a
very brief description of a few other skin disorders, primarily focusing on those that
respond to retinoid-related treatments.
Psoriasis is a common (3% of western population8) inflammatory autoimmune skin
disease. Interactions between keratinocytes, T cells, cytokines and chemokines all
contribute to psoriasis. Psoriatic epidermis displays keratinocyte hyperproliferation,
specifically increased stratum basale and stratum spinosum thickness (acanthosis), and
inflammatory cell accumulation. There are several subtypes (plaque, guttate, inverse,
pustular, erythrodermic, and others) and their symptoms include skin redness/irritation,
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itching (pruritus), lesions, pain, and increased risk of infection. Treatments for psoriasis
vary but often include combinations of steroids, vitamin D, phototherapy (UV exposure),
immunosuppressants, emollients, retinoids, and most recently, various biologics 8,58,59.
Acne vulgaris is a skin condition that nearly everyone has had some direct
experience with, particularly during adolescence (~90% of teenagers have acne 60). Acne is
caused by the blockage of sebaceous glands resulting in inflammation and lesions
(blackheads, whiteheads, pimples, etc.). Processes that contribute to this include abnormal
keratinocyte proliferation/desquamation, overproduction of sebum, bacterial infection
(Propionibacterium Acnes), and inflammation60. Acne, like most externally presenting skin
diseases, not only causes physical detriments, but also has a significant mental health
component which can cause great suffering for affected patients. Treatments include
retinoids, antibiotics, hormone therapies, and cleansing agents (salicylic acid, benzoyl
peroxide) aimed at desquamation, clearing blockages, and/or reducing bacterial infection 60.
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1.3 RETINOIDS AND RELATED COMPOUNDS
The term retinoid refers to the class of compounds chemically related to vitamin A.
Vitamin A specifically refers to retinol (ROL), while retinoids include the entire family of
bioactive metabolites and precursors of ROL including, but not limited to, retinal (RAL),
retinoic acid (RA), and the various synthetic analogs acting on endogenous retinoid
pathways (Figure 1.9). Due to the pleiotropic nature of retinoid biopathways, and their
essential and diverse cellular functions, retinoids are ubiquitously required in all stages of
human development. Vitamin A and its active metabolites play an essential role in many
biological processes including, but not limited to; vision, immunity, reproduction,
metabolism, neurologic function, development, and cellular differentiation 61.

Figure 1.9: Common retinoids in the vitamin A family.
Also showing the dietary retinal precursor, β-carotene.

1.3.1 RETINOID TARGETS AND MECHANISMS
Endogenous retinoids display a complex and essential role in many biological
processes and many of these roles still consist of incompletely defined mechanisms. A
review of 1,191 publications found over 532 genes that appear to be regulated by RA 62.
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This vast breadth of regulatory effects RA exerts on gene expression illustrates how
extensively retinoids contribute to our biology.
The primary targets of retinoids are nuclear receptors (NRs) including retinoic acid
receptors (RARs) and retinoid X receptors (RXRs) which, when activated, regulate gene
transcription. RARs consist of three subtypes, each with multiple isoforms (α1/2,
β1/2/3/4/1’, and γ1/2), and can be activated by either all-trans retinoic acid (atRA) or 9cis-RA. RXRs also consist of three subtypes, each with multiple isoforms (α1/2, β1/2, and
γ1/2), but are only known to be activated by the 9-cis form of RA (whether or not 9-cis RA
is the bona fide ligand is still up for debate)63. RARs form heterodimers with RXRs, which
will bind to specific DNA sequences called RA response elements (RAREs) found in the
regulatory regions of their target genes. RXRs can form a very diverse range of active
dimers as either homodimers or heterodimers with other NRs such as thyroid receptor (TR),
liver X receptor (LXR), peroxisome-proliferator-activated receptors (PPARs), vitamin D
receptor (VDR), and many others63 (Figure 1.10).
Recent discoveries have also revealed that RA can bind other NRs such as
PPARβ/δ, while other studies have found evidence of antagonistic interactions via RARrelated orphan receptor β (RORβ) and other NRs61. Further complicating the genomic
effects of RA is the deep involvement of coregulators (coactivators and corepressors),
which interact with RA-interacting NRs, and the variable sequences and geometries of
RAREs contributing to gene regulation63. RARs also display protein-protein interactions
with activator protein-1 (AP-1), a transcription factor regulating expression of cytokines,
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growth factors, metalloproteases, and many other targets. The RAR/RXR/AP-1 complex
acts to repress the expression of both RAR and AP-1 regulated genes 64 (Figure 1.10).

Figure 1.10: Illustration of some targets and biopathways of endogenous
retinoids. Both genomic and non-genomic effects, many of which remain poorly
understood, play a role in the biological effects of retinoids.
In addition to the genomic effects discussed above, retinoids also display nongenomic effects, an area of study which still requires significant research to properly define
and comprehend. Studies have shown that RA can activate several kinase cascades
including some mitogen-activated protein kinases (MAPKs) and extracellular signalregulated kinases (Erk)65. ROL has also be found to activate Janus kinases/signal
transducer and activator of transcription 5 (JAK/STAT5) 61. RA can also affect posttranslational protein modifications in a process called retinoylation 66 (Figure 1.10).
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1.3.1.1 RETINOIDS IN THE SKIN
Retinoids are found ubiquitously, and play many critical roles, in our bodies. Within
the skin, the roles of retinoids include regulation of keratinocyte proliferation,
differentiation, apoptosis, and maintaining barrier and immune functions 67. Endogenous
levels of retinoids can vary greatly from one individual to another; approximate
concentrations in healthy humans are ~2-4nM atRA and ~800nM ROL in the skin68, 414nM atRA and 1-2µM ROL in serum69.
RARγ and RARα are both found in the skin, although the levels of RARα are much
lower. RXRs are more abundant than RARs with RXRα being the most common subtype
in the skin. Unsurprisingly, the most commonly found RAR/RXR dimer pair within the
skin appears to be the RARγ-RXRα complex70.
Many cytokeratins (KRT5/6/14/17)71, the RA-transporting protein CRABP-II72, the
RA-metabolizing enzyme cytochrome P450 (CYP)26A1 73, and many other genes
expressed in the skin, contain RAREs within their promotor regions. There are many other
genes, including heparin-binding EGF-like growth factor (HBEGF), KRT1/2/4/10,
CYP26B1, and others, which are not known to contain RARE promotors, but are clearly
regulated by retinoids. A study investigating the effects of retinoids on the expression of
475 skin-related genes in reconstructed human epidermis found 44 genes were variably
expressed74. In addition to the genomic effects of retinoids, non-genomic targets such as
AP-1 (antagonized by RA and RARs) play an important role in epidermal differentiation 75.
The role of retinoids in skin barrier function include regulating epidermal
permeability, keratinocyte differentiation76, sebum production77, and apoptosis78. Studies
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have found that disrupting retinoid-related receptors in the skin results in epidermal
dysregulation79,80. Transgenic mice with complete loss of function of the RA-metabolizing
enzyme CYP26B1, leading to abnormally high RA levels, show decreased expression of
barrier proteins and barrier dysfunction81. Inhibition of retinoid signaling has also been
shown to cause disruption of the lipid barrier82. These studies, and many others showing
both increased and decreased retinoid signaling will disrupt barrier formation, together
illustrate a so-called “goldilocks” zone of retinoid signaling in the skin.
Retinoids also play an important role in maintaining epidermal immune functions
(previously discussed in Section 1.1.1.3) which contribute to the skin’s role in regulating
pathogen/allergen exposure and mediating inflammation. RAR and RXR pathways are also
involved in T helper cell development83–85 and retinoids are known to regulate cytokine
and chemokine levels86,87.
Due to the robust effects of retinoids in many skin functions, they are commonly
used in the treatment of many skin diseases (see Section 1.2). Keratinization and epidermal
proliferation disorders such as congenital ichthyosis41,49,88, psoriasis89–91, Darier’s
disease47,48, and many others respond to retinoid treatment and continue to be studied
within this context. Retinoids such as tretinoin, adapalene, and tazarotene are also used in
the treatment of mild- to severe- acne58. Retinoids have also shown promise in treating
inflammatory skin diseases such as atopic dermatitis68. Their ability to control cellular
differentiation and apoptosis have also led researchers to study retinoids for the prophylaxis
or treatment of skin cancers58.
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1.3.2 BIOSYNTHESIS, TRANSPORT & METABOLISM OF
ENDOGENOUS RETINOIDS
Retinol (ROL) is primarily obtained via its dietary precursors: animal-origin retinyl
esters (RE) and plant-origin carotenoids like β-carotene. Ingested dietary REs are
hydrolyzed to ROL in the intestines, absorbed, and complexed with cellular retinol binding
protein (CRBP)-II. Carotenoids are absorbed in the intestines, oxidized into retinal (RAL,
which can complex with CRBP-II as protection from oxidation), and reduced to ROL via
a retinal reductase. The ROL-CRBP-II complex can then interact with lecithin:retinol
acetyltransferase (LRAT) which catalyzes esterification of ROL to RE. RE is then
transported by chylomicron to the liver for long-term storage (50-80% of all the vitamin A
in the body is stored as RE). ROL is transported in the blood by the plasma transport protein
retinol binding protein (RBP), and delivered to its target cells 61,67 (Figure 1.1166).
Following uptake into keratinocytes, which is likely mediated by a cell surface RBP
receptor, ROL binds CRBP-I which assists in stabilization and transport 92. ROL will then
either be metabolized to RE by LRAT or acyl-CoA:retinol acyltransferase (ARAT) 93, or
reversibly converted to RAL by alcohol dehydrogenases (ADH) and short-chain
dehydrogenases/reductases (SDR). RAL can then be irreversibly converted to retinoic acid
(RA) by an aldehyde dehydrogenase (ALDH), namely, retinal dehydrogenase (RalDH)94.
RA will then bind cellular retinoic acid binding protein (CRABP) I or II, which can
facilitate either RA degradation or nuclear transport. CRABP has the highest affinity for
atRA, with low and no affinity for 9-cis-RA and 13-cis-RA, respectively95.
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Figure 1.11: Absorption, transport, and processing of retinoids. Retinyl
esters and β-carotenes found in our diet are intestinally absorbed, converted
to retinol in the liver, then distributed to its target cells where it is converted
to retinoic acid and exhibits its biological effects. CYP26 enzymes are
responsible for the metabolism of retinoic acid. TTR, transthyretine; RBP,
retinol binding protein; CRBP, cellular retinol binding protein; RDH,
retinol dehydrogenase; RALDH, retinaldehyde dehydrogenase; RAR,
retinoic acid receptor; RXR, retinoid X receptor.
Source: Das et al. (2014), with permission from Elsevier (lic. #:
4606690534887)
RA metabolism is catalyzed by heme-containing cytochrome P450 enzymes
(CYPs), a superfamily of 57 [in humans] enzymes responsible for the metabolism of many
endogenous and exogenous compounds, as well as an estimated 75% of marketed
pharmaceuticals drugs96. The CYP26 family is the primary enzyme responsible for
metabolism of RA, however, other non-RA-specific CYPs have also been reported to
metabolize RA97. CYP26 enzymes (three human isoforms: CYP26A1, CYP26B1,
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CYP26C1) are unique due to their selectivity for RA metabolism. CYP26 research has
primarily focused on the CYP26A1 and CYP26B1 isoforms in part due to the low levels
of CYP26C1 expression seen in adult human tissues98. In vitro and in vivo studies have
shown autoinduction of CYP26A1 expression by RA 99–101, a mechanism generally
accepted to be controlled by RAR/RXRs bindings to RAREs found in the promotor region
of many RA-regulated genes102,103. CYP26B1 gene expression is also induced by RA,
however, only CYP26A1’s promotor has been found to contain a RARE 73. Tissue
distribution of each isoform varies (e.g. CYP26A1 is the primary hepatic isoform 97,
CYP26B1 the primary brain isoform98), however, both can be found in skin tissue. Studies
have found that CYP26A1 expression tends to be restricted to basal epidermal
keratinocytes104, while CYP26B1 has greater expression in the dermis and hair follicles
than the epidermis81.

1.4 RETINOIC ACID METABOLISM BLOCKING AGENTS
Retinoid therapies (available in oral and topical formulations) have successfully
been used in the treatment of a variety of skin diseases (detailed in Section 1.2). These
include endogenous retinoids like all-trans RA (tretinoin) and 13-cis RA (isotretinoin), and
synthetics including tazarotene, adapalene, and many others. Although retinoids are
commonly used in clinical settings, the adverse effects of these drugs (e.g. skin irritation,
dryness, photosensitivity, hyperlipidemia, hyperostosis, teratogenicity, and more) 58 can
result in complications or noncompliance in many patients.
To address adverse effects and the issue of tolerance (resulting from autoinduction
of its metabolism) by direct retinoid therapy, a new class of drugs called retinoic acid
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metabolism blocking agents (RAMBAs) were developed. These act by blocking RA
metabolism via selective inhibition of CYP26-mediated RA metabolism 105.

Figure 1.12: Non-erythrodermic lamellar ichthyosis patient treated with 5%
topical liarozole showing marked improvement. (a) before treatment, (b)
patient's left side treated with liarozole & patient’s right side treated with vehicle
only, (c) liarozole treatment on both sides.
Source: Lucker et al. (2005), with permission from John Wiley and Sons (lic. #:
4606590968295)
The antifungal agent ketoconazole was the first studied after it was found to inhibit
CYP-mediated RA metabolism, however, its use was short lived due to off-target
activity106. The first-generation of CYP26-specific RAMBAs such as liarozole (Figure
1.13), successfully inhibited the metabolism of RA 107 and showed great promise in treating
several skin disorders41,88,90,91,108,109 including psoriasis and ichthyosis (Figure 1.1241).
Liarozole, although extensively studied and progressing to late-stage clinical trials,
displayed non-specific effects including interference of hormone biosynthesis 106, which
may be the reason they have not progressed to clinical use in the US. The more selective
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and potent RAMBA, talarozole (R115866) (Figure 1.13), was synthesized to address the
issues seen with liarozole110. Talarozole has also been shown to alter the expression of
retinoid-related genes111 and underwent several successful topical and oral clinical trials
for the treatment of acne and psoriasis89,112, however, development was halted in 2008,
likely for budgetary reasons113.

Figure 1.13: Structures of several RAMBAs. First-generation (top) and
two of the novel candidate compounds developed by Diaz et al. (bottom).
These next-generation RAMBAs lack the azole moiety found on the
previous generations, which should reduce their off-target activity.

In response to this gap in the development of CYP26-inhibitors, Diaz et al., have
synthesized and screened a library of compounds with varying selectivity for the different
CYP26 isoforms114,115 (Figure 1.13). The previous generation RAMBAs contain an azole
moiety, which can interact with the heme found in all CYPs, is thought to contribute to
their lack of specificity. The compounds developed by Diaz et al. aim to increase CYP26
specificity with a series of compounds lacking this azole moiety, then, by studying
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candidates with varying the isoform specificity, elucidate the advantages each. Initial
screening of several early development compounds showed high CYP26 specificity and
potency, with little detectable direct activation of RAR114.

1.4.1 CYP26B1-SELECTIVE RAMBA: DX314
DX314 (previously referred to as NMP314) is a novel CYP26B1-selective
RAMBA previously described and patented116 by Diaz et al. In these studies, we focus
primarily on DX314 (Figure 1.13), a CYP26B1-selective compound with a 16-fold higher
selectivity for CYP26B1 over CYP26A1, and no detected inhibition of CYP19 (estrogen
synthase), in contrast to liarozole and talarozole (Table 1.2114,116,117). DX314’s cytotoxicity
was previously assessed (data not shown) in human keratinocyte, dermal papilla cell, and
SH-SY5Y monolayer cultures, which found no evidence of significantly decreased cell
viability within the dose ranges used in this study.

31

Table 1.2: Previous and novel RAMBA cytochrome P-450 IC50 values. CYP26A1
and CYP26B1 were expressed in SF9 cells and prepared as microsomal fractions.
100nM 9-cis-RA was used as the substrate and formation of the metabolite 9-cis-OHRA was measured by HPLC. Estimated IC50 was determined by: 𝟏𝟎𝟎% ∙
𝒗𝒊
𝒗 𝒎𝒊𝒏

∙ 𝟏𝟎𝟎% +

𝒗𝒊
𝒗 𝒎𝒂𝒙

𝟏

𝒗𝒊
∙𝟏𝟎𝟎%
𝒗 𝒎𝒊𝒏
(𝑰
𝐥𝐨𝐠
𝑰𝑪
𝟓𝟎 )
𝟏𝟎

𝒗𝒊
𝒗

=

. CYP2C8, CYP3A4, and CYP19 inhibition

assays were performed in pooled human liver microsomes using paclitaxel (4µM),
midazolam (0.5µM), and estrone (1µM), as the respective substrates. Product
formation was measured by LC-MS/MS. * = unpublished data.
CYP26A1 CYP26B1
IC50 (nM) IC50 (nM)
Liarozole
Talarozole
DX314
(#39)
DX308
(#38)
DX385
(#44)

CYP2C8 CYP3A4
IC50
IC50
(nM)
(nM)
480
10,000
[1,300]
[1,220]

CYP19
activity @
1µM (%)

Reference
(PMID)
26918322114
[28275201]161
26918322
[10734183]110

1,900
[3,200]
5.1
[4]

18
880*
0.46

220

470

63.6*

1,752

108

>1,000*

2,400*

102.1*

Patent116

51

51

>1,000*

24,000*

98.5 (@
0.1µM)*

Patent

340

14,500

>1,000*

>50,000*

98.4*

Patent
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16.2*

2. DX314 POTENTIATES THE EFFECTS OF RA, WHILE
PROTECTING BARRIER FUNCTION IN
RECONSTRUCTED EPIDERMIS
2.1 INTRODUCTION
During initial studies, a library of several of candidate compounds having
previously undergone in silico and in vitro CYP26-inhibition assays, were investigated for
cytotoxicity and retinoid-responsive gene expression changes within simple monolayer
keratinocyte cultures. Two compounds; DX308, and this study’s focus DX314, were
selected for further study. Here we focus on the characterization of DX314, which became
our primary focus as it displayed the least evidence of non-specific biological effects.
The aim of these studies is to investigate whether DX314 can potentiate the effects
of endogenous levels of atRA, and consequently mimic the desired biological effects seen
in retinoid-based therapies, with minimal evidence of undesirable effects. For the purpose
of these studies, a potentiation of atRA is defined as the ability of a compound cotreated
with low-dose atRA to display: an effect significantly different from control given said
effect can be seen when treating with atRA alone; an effect size larger than what is seen
with low-dose (1nM) atRA alone; and in a manner mimicking the effects seen when
treating with higher-dose atRA alone. A RAMBA displaying little or no effect on its own
but displaying a potentiation of atRA when they are cotreated, implies the RAMBA acts
by inhibiting the metabolism of atRA. This would result in identical initial doses of atRA
producing a relatively increased effect in the presence of a RAMBA. These studies were
performed in reconstructed human epidermis (RHE) grown using primary keratinocytes
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from healthy adult donors. Use of in vitro 3D skin models provides significant
improvements in study relevance to in vivo conditions relative to the traditional monolayer
keratinocyte culture. Two independent studies (Table 2.1) characterizing the effects of
DX314 in healthy RHE are presented here. The effects of atRA, as well as the well-studied
RAMBA liarozole, are used to compare the therapeutic potential of DX314.
Cells
Experiment
1

NAK209
NAK214
NAK219

Experiment
Gibco
2
C00505C

Assays

Groups

qPCR

1

Histology

2

IHC/IF

2

TEER

1, 2

RNAseq

3

TEER

3

IPA

3

TEWL
4
Table 2.1: Outline of experiments performed
during this study. IPA, Ingenuity Pathway
Analysis;

IHC/IF,

immunofluorescence;

Immunohistochemistry/
TEER,

transepithelial

electrical resistance; TEWL, trans-epidermal
water loss.
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2.2 METHODS
2.2.1 PRIMARY HUMAN KERATINOCYTES
Primary, human, adult, healthy, epidermal keratinocytes were used for all parts of
this project. Adult, human epidermal keratinocytes (HEKa, Gibco, C-005-5C) were
sourced from a 40yo female. NAK209 (48yo, female), NAK214 (37yo, male), and
NAK219 (32yo, female) were generously donated to the project by our collaborator, Dr.
Yves Poumay at the University of Namur, Belgium.

2.2.2 CELL CULTURE
The keratinocytes were previously isolated by the Poumay lab from skin biopsies
as described118–120. Excess skin tissue from abdominoplasty was stored in a 4°C saline
solution for transport to the lab. In a sterile culture hood, the tissue was placed into a petri
dish containing solution A (10mM Glucose, 2mM KCl, 130mM NaCl, 1mM Na 2HPO4,
3.3μM phenol red, 30mM HEPES, pH 7.2-7.4, 0.22µm sterile filtered) and cut into 1-2cm 2
sections. The sections are then transferred to a petri dish containing a 4°C trypsin solution
(0.17% w/v trypsin, 50µg/mL gentamycin, 250ng/mL fungizone, and 250ng/mL ampicillin
in solution A) and incubated overnight at 4°C. The dermis and epidermis are then separated
using sterile forceps and the epidermis placed in solution A containing 2% dialyzed fetal
bovine serum (FBS) for further dissociation by manual stirring. The suspension is then
filtered through a 70µm cell strainer, centrifuged for 10min at 160rcf and 4°C, and
resuspended in 10mL KGM-2 bullet kit (Lonza, CC3107) supplemented with gentamycin,
fungizone, and ampicillin in the concentrations described above. The viable cell count is
determined with a Countess automated cell counter (Invitrogen), then 46,000 cells/cm 2 are
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plated in a 175cm2 culture flasks containing 25µL FBS and 25mL KGM-2 supplemented
with 0.5% penicillin/streptomycin (P/S, Corning, 30002CI). This is incubated undisturbed
for 3 days in a 37°C, 5% CO2, humidified incubator. The media is then replaced with
Epilife Complete (Epilife media [Gibco, MEPI500CA], 1% HKGS [Gibco, S0015], 0.5%
P/S), which is replaced every two days, and allowed to reach 50-60% confluence before
subculturing or cryopreservation at 1e6 cells/mL in freezing media. (Epilife, 10% DMSO,
10% FBS).
Keratinocyte culture protocols were adapted from the protocol described by
Poumay et al.121. Briefly, cryopreserved cells were thawed and seeded in cell culture flasks
at 3000-12000 cells/cm2 in KGM-2 (supplemented with 0.5% penicillin/streptomycin) and
placed in a 37°C, 5% CO2, humidified incubator for 24hrs. Media was then replaced with
Epilife Complete, refreshed every 2 days, until ~60-70% confluence. The cells are then
trypsinized (0.025% trypsin/0.01% EDTA), neutralized, counted, and used for RHE or
autocrine monolayer culture.

2.2.2.1 RECONSTRUCTED HUMAN EPIDERMIS
The RHE protocol was adapted from the protocol described by Poumay et al. 118–
120

. Briefly, 2.5mL of RHE Day 0 media (Epilife Complete with 1.5mM CaCl 2) is placed

into each well of a 6-well cell culture plate. A 12mm diameter, polycarbonate membrane
(0.4µm pore-size), cell culture insert (Millipore, PIHP01250), is then placed into each well
using sterile tweezers. Keratinocytes (passage 3 or 4) are suspended in Epilife Complete at
4e5 cells/mL, and 500µL of this cell suspension is pipetted into each insert (resulting in
200k cells/insert). The plates are then placed in a 37°C, 5% CO 2, humidified incubator, and
36

left undisturbed for ~24hrs. The following day, the media is aspirated and replaced with
1.5mL RHE Day 1+ media (RHE Day 0 media with 10ng/mL human keratinocyte growth
factor [Sigma, K1757] and 50µg/mL vitamin C), which was subsequently changed every
two days for the remainder of the experiment. Any media remaining on the surface of each
tissue is carefully aspirated to establish an air-tissue interface, which promotes
differentiation and epidermal stratification. Drying of the RHE surface was done daily until
the barrier is fully formed and media is no longer appearing on the tissue surface. RHEs
were grown for a total of 11 days, treatments were started on day 7, refreshed day 9, and
stopped on day 11 (Figure 2.1). All treatment groups (including controls) contained 0.1%
DMSO as a vehicle to aid compound solubility. Preparation of any photosensitive
compounds (i.e. retinoic acid) was performed in a dark culture hood with minimal ambient
light. Following treatment, the RHEs were collected for RNA purification (Section 2.2.6.1)
or histology (Section 2.2.5).

Figure 2.1: Timeline of RHE growth and treatment. Media Δ, media change;
RHE, reconstructed human epidermis; TEER, transepithelial electrical resistance;
TEWL, trans-epidermal water loss.

2.2.3 TEWL
A custom protocol was developed to allow for a minimally invasive and disruptive
measurement of TEWL in viable RHE. This method was required to minimize physical
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contact with the tissue surface, allow the tissue to remain within the insert, and to not
interfere with downstream experiments, including TEER and histology on the same tissue.
Typical in vitro methods to quantify TEWL either required the tissue to mounted to a Franz
cell (which requires it to be removed from the insert), or use of an evaporimeter attachment,
which makes direct contact with the tissue surface and could potentially damage the thin
tissue. For this reason, we constructed flexible rubber seals (using gaskets and washers
purchased at a local hardware store and assembled with a flexible silicone-based adhesive),
which could be sterilized in a solution of 70% ethanol. This allowed the evaporimeter to
form an airtight seal over the insert, ensuring any measured water flux must have diffused
through the tissue (Figure 1.8). If both TEWL and TEER were measured within a single
experiment, TEWL was measured first, followed by a minimum of 2hrs of recovery time
in the incubator before TEER is measured. Because TEER requires each tissue to be
submerged in media, the residual moisture from this assay would have interfered with the
sensitive TEWL measure.
Plates were removed from the incubator and placed in the tissue culture hood with
their lids slightly ajar for 15min to allow for adjustment to ambient humidity. Tissue
surfaces were thoroughly checked for any moisture, and if needed, lightly dabbed with a
sterile cotton swab. The plate was placed on a 37°C plate warmer to ensure consistent
media/tissue temperature and promote diffusion and formation of water vapor at a
physiologically relevant temperature. The custom rubber seal was fitted over the insert to
form an airtight seal between the tissue and the AquaFlux AF200 evaporimeter (Biox)
measurement head. TEWL was measured before (day 7) and after (day 11) treatment
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(Figure 2.1), over 60-90s, as recommended by the manufacturer, until a steady state water
flux was achieved. Due to the inherent sensitivity of TEWL measurements, after each tissue
on a plate was measured once, they were sequentially measured a second time and the two
values were combined into a single datapoint for statistical analysis.

2.2.4 TEER
The TEER protocol was adapted from a protocol developed by the Poumay lab,
which was communicated by personal correspondence. Under sterile conditions, 4mL of
Epilife media was placed into each well of a 6-well plate (a separate well for each unique
treatment to prevent cross-contamination) and allow to come to room temperature. Use
sterile tweezers to transfer an RHE into the media, then pipette 500µL of the underlying
media into the insert (3.5mL of media remains in the bottom of the well). Allow the tissue
to remain submerged for 30sec before inserting the sterile electrode (Millicell ERS-2)
(Figure 1.7). Ideally, we would allow the TEER measure to come to a steady state before
reading, however, we found that in many cases this could take in excess of 10min per tissue.
We believe this is due to a slow diffusion of media into the tissue affecting the electrical
resistance, thus causing the reading to continuously drift. For this reason, we arbitrarily
choose a consistent 30sec measurement period for all tissues and recorded the TEER at the
end of that period. After measurement, the media in the insert was aspirated and placed
back into the well, the tissue surface was dried, and the RHE was placed back into its
growth plate. TEER was measured before (day 7) and after (day 11) treatment, and
occasionally halfway through (day 9) treatment (Figure 2.1).
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2.2.5 HISTOLOGY
Preparation of RHE for histological analysis is described in the RHE protocols
above119,120. Following treatment, RHEs were immediately placed in a fixing buffer, which
consists of 4% formaldehyde and 1% glacial acetic acid. The following day, the tissues
were dehydrated with sequential methanol washes (1x rinse, 1x 5min wash, 2x 10min
wash), removed from the insert, briefly rinsed in toluene, then placed in fresh toluene bath
for 1hr at room temperature. The tissue was then rinsed in liquified paraffin and transferred
to fresh liquified paraffin at 58°C for 1hr to allow for complete toluene-paraffin exchange.
Finally, the tissue was perpendicularly mounted in a mold containing fresh liquified
paraffin, covered by a histology cassette, and allowed to solidify. A microtome was used
to take 6µm vertical sections from a depth of at least 1.5mm into the 12mm diameter RHE.
Sections were mounted to positively charged glass slides and allowed to dry before use.
Deparaffinization of the slides was performed in the following steps: 2x 3min
toluene, 2x 3min methanol, 2x 3min 70% methanol, 10min circulating tap water rinse. The
slides were then immediately used for hematoxylin-eosin (HE, Section 2.2.5.1) or
immunohistological (Section 2.2.5.2) staining.

2.2.5.1 HEMATOXYLIN-EOSIN STAIN
Slides were sequentially exposed to the following baths: 3x 3min hematoxylin
solution, 3min circulating tap water, 3min ethanol with 0.15% HCl, 10min circulating tap
water, 2x 3min eosin solution, 3min circulating tap water, 3min 70% ethanol, 3x 3min
isopropanol, 3min toluene. Coverslips were mounted, and the adhesive allowed to dry
before imaging on an Olympus DX63 microscope with Olympus SC50 camera.
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2.2.5.2 IMMUNOHISTOLOGY
Slides were sequentially exposed to the following: PBS rinse, 2x 3min 0.1M
glycine in dH2O, PBS rinse, then 1hr in PBS/BSA/Triton (PBS with 0.2% BSA and 0.02%
Triton X-100). A hydrophobic marker was used to encircle the tissue and 50µL of primary
antibody (diluted in PBS/BSA/Triton) was applied. The slides were placed in a humidity
chamber and incubated for 1hr at room temperature. The slides were then rinsed three times
in PBS/BSA/Triton before 1hr humidified incubation with 50µL of the respective
secondary antibody. The slides were again rinsed three times in PBS/BSA/Triton before a
15min incubation with 50µL of Hoechst nuclear stain (diluted in PBS/BSA/Triton)
followed by 3x 5min PBS rinses. Coverslips were mounted with Mowiol and the slides
were stored at 4°C until imaged on an Olympus DX63 microscope with Olympus XM10
camera. Primary and secondary antibody sources and dilutions can be found below (Table
2.2).
Target
Species
Dilution
Source
IVL
Mouse
1:200
Invitrogen, I9018
CYP26A1
Mouse
1:50
Santa Cruz, SC53618
CYP26B1
Mouse
1:50
Santa Cruz, SC293493
FLG
Mouse
1:75
ThermoFisher MA5-13440
KRT10
Mouse
1:100
DAKO, M7002
KRT14
Mouse
1:50
Santa Cruz, SC58724
2°, HRP-conjugated
Horse
1:100
Vectastain, PK-4002
(anti-mouse)
2°, Alexa Fluor
488-conjugated
Goat
1:1000
Life Technologies, A11001
(anti-mouse)
Hoechst 33258,
1:100
Life Technologies, H3569
nuclear stain
Table 2.2: Antibodies and dyes used for immunohistological staining.
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2.2.6 DIFFERENTIAL GENE EXPRESSION
2.2.6.1 RNA ISOLATION
Following treatment, RHEs intended for RNA extraction were flash frozen at -80°C
until use. RNA was isolated using the NucleoSpin RNA (Macherey-Nagel, 740955) kit, as
recommended by the manufacturer. Variations from the standard protocol include:
homogenization with 600µL (rather than 350µL) of RA1 lysis buffer, addition of 6µL of
β-mercaptoethanol to RA1 to aid tissue lysis, and addition 600µL of 70% ethanol (rather
than 350µL) during nucleic acid precipitation.

2.2.6.2 RT qPCR
Isolated RNA purity and concentration were measured by NanoDrop 2000c
(Thermo Scientific) and integrity was confirmed by gel electrophoresis. For each reaction,
6.5µL of a mix containing; 100-200ng of template RNA, 50ng/mL oligo(dT)12-18 (Life
Technologies,

58862),

and

0.5mM

dNTP

mix

(Invitrogen,

10216018/10219012/10217016/10218014), were incubated at 65°C for 5min. 3.5uL of the
Superscript III reverse transcriptase kit (Invitrogen, 18080044), which includes enzyme
(56575), DTT (Y00147), and 5x first-strand buffer (Y02321), is then added to each well
and incubated for 50min at 42°C, followed by 15min at 70°C. The cDNA was then diluted
1:10 with water. 2µL of cDNA was added to a 10µL real-time qPCR reaction, which used
Takyon No ROX SYBR 2X MasterMix (Eurogentec, UF-NSMT-B0701) on a Roche
Lightcycler 96 (activation: 3min - 95°C; 40 cycles: 10sec - 95°C, 20sec - 60°C, 30sec 72°C). 500nM of each primer pair (Table 2.3), optimized for an annealing temperature of
60°C, was used for each reaction. RPL13a and 36B4 (RPLP0) were used as reference
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genes. Every reaction was performed in technical duplicates. Due to limited access to donor
tissue, and the low cellular passage number necessary for quality RHE, the qPCR results
obtained during experiment 1 (Table 2.1) consists of pooled data from replicate
experiments consisting of RHE from several donors. Because these independent replicates
are subject to the interindividual variability in treatment response by each donor, we
applied a method described by Willems et al.122 to standardize the qPCR data, determine
the fold-change in expression from control, and calculate the 95% confidence interval of
the mean. Statistical analysis was done by one-way ANOVA with Dunnett’s correction for
multiple comparisons on the standardized values using GraphPad Prism 6.
Target

Forward
Reverse
5’-ATC AAC GGG TAC AAA 5’-CAG ATG GAT CAG CCA
36B4
CGA GTC-3’
AGA AGG-3’
5’-CTC AAG GTC GTG CGT
5’-TGG CTG TCA CTG CCT
RPL13a
CTG AA-3’
GGT ACT-3’
5’-TGG CCC TCC ACT CCT
5’-GGG TCA CAG AAC CAT
HBEGF
CAT C-3’
CCT AGC T-3’
5’-TGA AAC AGC CAA CTC
5’-TTC CTC TTG CTT TGA
IVL
CAC-3’
TGG G-3’;
5’-ATC GAT GAC CTT AAA
5’-GCA GAG CTA CCT CAT
KRT10
AAT CAG ATT CTC-3’
TCT CAT AC-3’
5’-CGA TGG CAA GGT GGT 5’-GGG TGA AGC AGG GTC
KRT14
GTC-3’
CAG-3’
5’-GGG AGA GCG GCT GGA 5’-TCC AAA GAG GAG TTC
CYP26A1
CAT-3’
GGT TGA-3’
5’-CCG CTT CCA TTA CCT
5’-CCA CCG CCA GCA CCT
CYP26B1
CCC GTT C-3’
TCA G-3’
5’-GGG CAC TGA AAG GCA
5’-CAC CAT AAT CAT AAT
FLG
AAA AG-3’
CTG CAC TAC CA-3’
5’-GTC GTC TTC CGG CTC
5’-TCA CTG TTT CAT TGC
TGM1
GAA-3’
CTC CAA T-3’
5’-TCC CTG TGT TTG CTG
5’-GAA CAG TCC CAG TAT
STRA6
CT-3’
CTT CCA G-3’
Table 2.3: List of primers used for qPCR. Integrated DNA Technologies (IDT)
IDs: i - Hs.PT.58.38635764, ii - Hs.PT.58.38517191, iii - Hs.PT.58.3346779.g.
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Ref
121
123
121
121

i
123
121

ii
123
123

iii
assay

2.2.6.3 RNA SEQUENCING & BIOINFORMATICS
RNA samples were sent to the University of Colorado’s Genomics and Sequencing
Core Facility (Denver) for library preparation and sequencing. Purity and concentration
were measured with an Agilent Bioanalyzer (Agilent Technology). 200-500ng of RNA was
used to prepare the Illumina HiSeq libraries according to manufacturer’s instructions for
the TruSeq Stranded RNA kit (Illumina). Sequencing was done as 2x 151bp paired end
reads on the Illumina HiSeq4000.
Raw data was delivered to us as FASTQ files (two paired files per sample), which
contained RNA sequences, each with a length of 151 bases (b), as well as a quality score
metric (Q) per base read, which indicates the probability (P) that the respective nucleotide
was incorrectly identified by the sequencer. This score is defined as: 𝑄 = −10 ∙ log

𝑃.

A sequence score ≥ 30 (indicating a P ≤ 0.001) is typically considered acceptable for
analysis. As delivered, sequencing across all samples had an average quality score of 35.2
(lowest quality sample scoring a mean of 34.9 across all sequences), with the total reads
per sample averaging 12.4Gb (smallest sample size: 9.2Gb).
The bioinformatics pipeline we used was an adaptation of several previously
described methods124–130, and was applied in the following sequence: FastQC130 (v0.11.5)
→ Trimmomatic128 (v0.38) → FastQC → HiSat2129 (v2.1.0) → SamTools131 (v1.8) →
StringTie125 (v1.3.4d). FastQC analyzes the FASTQ files to determine the quality of the
reads before, and after, trimming to ensure acceptable read quality for downstream
analysis. Trimmomatic then processes each sequence within a set of paired FASTQ files
to remove the adapter sequences, which were added to the RNA fragments during library
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preparation for sample identification. Trimmomatic also applies quality filtering using a
sliding window approach to, starting on the 5’ end of the read, scan 4b fragments and trim
the 3’ end if any group falls below a mean quality score of 15. Trimmomatic was also
instructed to remove any sequences trimmed below 36b from the dataset, which helps
prevent false positives during alignment. Trimming resulted in an average of 0.57% (SD =
0.13%) of the paired sequences being dropped completely, 59.5% (SD = 11.7%) paired
survivors, 39.5% (SD = 8.6%) forward only survivors, and 0.47% (SD = 0.09%) reverse
only survivors. The resulting paired read outputs were used for alignment, while unpaired
sequences were excluded from further analysis. The trimmed paired FASTQ files were
reanalyzed in FASTQC to confirm sequence quality was maintained during trimming. The
HiSat2 package was used to align each sequence to a reference human genome (H. sapien
GRCh38 genome_tran index, provided by the HiSat2 developers132 and indexed with the
included shell script). HiSAT2 exports a sequence alignment map (SAM)-formatted file,
which contains information on each alignment including: the sequence aligned, the location
of each sequence within the genome, the quality of the alignment, the sequence length, and
more. SamTools is then used to convert the text-based SAM file to a binary alignment map
(BAM) file to allow annotation and qualification by the StringTie package. StringTie
accepts a BAM file as well as a gene transfer format (GTF) file (also built by shell script
included with the GRCh38 genome_tran index), which contains the names and locations
of known genes, transcripts, introns, and exons in the reference genome. StringTie’s
network flow algorithm will also identify and account for various isoforms of a given gene,
even if they are not explicitly defined in the user provided annotation. The final output of
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StringTie provides a GTF-formatted count table containing the Ensembl ID for each
transcript, as well as the number of matching sequences in the sample. The StringTie
developers also provide a small script (prepDE.py), which was used to combine the
individual GTF files to a single count table formatted as a comma-separated value (CSV)
file, which contains one gene per row with the gene IDs in the first column, one sample per
subsequent column, and the number of transcripts found during alignment in each
corresponding cell.
This gene count table can then be imported by the R 133 (v3.5.2) package
DESeq2126,127,134 (v1.22.2) for differential expression analysis. DESeq2 was set up to group
treatment replicates and determine the fold-change in gene expression from the control
group for each treatment. BiomaRt135 (v2.38.0) was then used to attach the HUGO Gene
Nomenclature Committee (HGNC) gene symbols to each Ensembl ID. Finally, DESeq2
normalizes the raw read counts based on the differential read depth for each sample, applies
logarithmic-fold change shrinkage to correct for effect size using the apeglm 136 (v1.4.2)
algorithm, and computes the false-discovery rate (FDR) statistic with the default
Benjamini-Hochberg correction for multiple comparisons. The final output consists of one
CSV file per comparison (treatment) containing one gene per row (annotated with Ensembl
ID and HGNC symbol) as well as the mean fold-change in expression and FDR statistic
for each comparison. Individual treatments were then merged (by matching gene IDs) into
a single CSV containing the fold-change in expression and FDR for every treatment group
in the study.
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Treatment groups & sample sizes: Control (0.1% DMSO, n = 5), 1nM atRA (n =
4), 100nM atRA (n = 4), 1000nM DX314 (n = 3), and 1000nM DX314 + 1nM atRA (n =
4).

The

scripts

used

for

bioinformatic

analysis

can

be

found

here:

https://github.com/JGSV/DX314_Bioinformatics/.
2.2.6.3.1 PATHWAY AND REGULATOR ANALYSIS
The output of the procedure detailed above, which contains each treatment’s mean
fold-change in expression from control, and their respective FDR values, mapped to
Ensembl IDs were imported into Ingenuity Pathway Analysis137 (IPA, Qiagen) software
for pathway analysis. This software utilizes an expert-curated knowledgebase containing
millions of peer reviewed findings and datasets, to allow for in depth investigation into
complex biological pathways, networks, regulators, and more. We selected to limit the IPA
analysis (which used the most up-to-date database available as of January 20 th, 2019) to
only consider genes with an FDR ≤ 0.05 and a fold-change in expression greater than 1.5,
or less than -1.5. IPA utilizes Fisher’s exact test (we accepted the recommended
significance cutoff of p ≤ 0.05) to predict which canonical pathways and upstream
regulators are activated, inhibited, or unaffected. IPA was instructed to only consider
upstream regulators which fell under the following IPA-provided categories: “genes, RNA,
proteins, and endogenous chemicals”. The relative strength and direction of each prediction
is given as a z-score. As per IPA’s recommendation, a z-score of ≥ 2.0 was considered
activated, while a z-score ≤ -2.0 was considered inhibited.
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2.3 RESULTS
2.3.1 DX314 POTENTIATES THE EXPRESSION OF RETINOIDRESPONSIVE GENES WHEN CO-TREATED WITH
NANOMOLAR atRA
In the first series of experiments, RHE made with primary keratinocytes from three
adult donors were treated with variable doses of atRA or RAMBAs (DX314 or liarozole)
with, or without 1nM atRA. Alterations in the mRNA expression of several genes related
to keratinocyte differentiation or retinoid bioactivity were observed using real-time,
quantitative polymerase chain reaction (RT-qPCR) (Figure 2.2). Due to inherently high
interindividual and interexperimental variability, the raw data was standardized as
described by Willems et al.122 across independent experimental replicates. After treatment
with atRA alone, an increase in HBEGF, CYP26A1 and CYP26B1 expression is observed.
A subtle, yet significant, increase in expression is also observed in IVL at a dose of 100nM.
Since culture media does not initially contain RA, RAMBAs alone should exhibit no effect
if their action is through enhancement of RA concentration. We herein confirm that neither
DX314 nor liarozole alone had significant effect on the expression of the genes analyzed
in this study. On the contrary, we found that 1000nM DX314 combined with 1nM atRA
was able to mimic the consequences of high dose atRA on the expression of every gene
analyzed here. 100nM DX314 with 1nM atRA also achieved this effect on HBEGF and
IVL. Liarozole with atRA was only able to significantly alter HBEGF and CYP26A1
expression but did so each dose studied. Overall, these results do appear to support the
hypothesis that the RAMBAs potentiate the effect of low dose atRA on these genes,
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however, we did experience a large variance in the replicates, which, we believe, was due
to the inherent interindividual variability in response by different donors.
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Figure 2.2: Variable gene expression of RHE treated with atRA, RAMBAs.
Expression of HBEGF (a-d), IVL (e-h), CYP26A1 (i-l) and CYP26B1 (m-p) mRNA
after 4-day treatment with atRA or RAMBAs, with (grey bars), and without (white
bars), 1nM atRA. Data includes pooled results of RHE grown using keratinocytes from
one of three donors. Solid line below shows control, while the dotted line shows 1nM
atRA. Bars show mean ± 95% CI. Significance vs vehicle control determined by oneway ANOVA with Dunnett’s correction for multiple comparisons on autoscaled
values. *p≤0.05; **p≤0.01; ***p≤0.001. n = 4 in all groups except: 1000nM DX314
(with/without atRA) and 2000nM liarozole (with/without atRA); n=3. Note: CYP26A1
controls showed no detectible fluorescence after 40 qPCR cycles. To allow for
presentation of data a target Ct value of 40 was assigned to undetected samples.
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Immunohistochemical staining of the RHE shows IVL primarily localized in the
upper layers of the epidermis in the control and 100nM DX314 treatment groups (Figure
2.3). 1nM and 100nM atRA, as well as 100nM DX314 + 1nM atRA, all show earlier IVL
expression within the lower layers suggesting a modification of differentiation by atRA
and supporting the potentiating effect of DX314. Immunostaining of CYP26A1 and
CYP26B1 (Figure 2.4) were also performed but the results were disorganized and
inconsistent with mRNA expression patterns. Irregularities and a lack of correlation
between CYP26 mRNA and protein expression has previously been observed in in vitro138
and in vivo111,139 studies of RAMBA treated ichthyotic and healthy skin.

Figure 2.3: Changes in involucrin (IVL) localization by atRA, DX314.
Comparison of healthy RHE processed for IHC detection of late differentiation
marker, IVL, following a 4 day of treatment with atRA, DX314, or DX314 + atRA.
Scale bar = 20µm.
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CYP26A1

CYP26B1
Figure 2.4: Immunofluorescent staining of CYP26 in healthy RHE. RHE were
stained with antibodies targeting CYP26A1 (top, green), CYP26B1 (bottom,
green), and a nuclear stain (blue).
To address the variance in gene expression seen in in the first series of experiments
and confirm the ability of DX314 to potentiate the effects of low dose atRA, we designed
the second series of experiments, to use a single source of healthy, primary keratinocytes
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for all replicates. In this experiment, we performed RNA sequencing (RNAseq) which
allows simultaneous investigation of all expressed transcripts in a sample and quantify
differential expression across treatments. The RNAseq results confirm that 1000nM
DX314 alone has no effect on HBEGF, IVL, CYP26A1 or CYP26B1 mRNA expression.
However, DX314 conversely demonstrates potentiation of atRA effects when cotreatment
is performed (Figure 2.5). We also present a gamut of known retinoid-responsive genes
including several keratins (KRT)71, lecithin:retinol acyl- transferase (LRAT)93, retinol
binding protein 1 (RBP1)140, and cellular retinoic acid binding protein 2 (CRABP2)141
which also show a potentiation of atRA by DX314. In the adjacent left column of the figure,
we show whether a particular gene involves direct (green = RAREs present within
promotor71,100,142–148), or indirect/unknown (white = no known RAREs in promotor) RA
pathways. Overall, the RNAseq experiment displays gene expression patterns which
provide strong evidence that DX314 inhibits atRA metabolism, thereby potentiating its
effects.
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Figure 2.5: Gene expression by RNAseq in RHE treated with atRA,
DX314. Fold-change in expression vs vehicle control. RHE treated with 1nM
atRA (left column), 100nM atRA (middle-left column), 1000nM DX314
(middle-right column), or 1000nM DX314 + 1nM atRA (right column). Dark
grey cells indicate a lack of statistical significance, while all colored cells are
considered statistically significant (FDR ≤ 0.05). An adjacent green box
indicates the gene shows evidence of RAR-mediated expression effects based
on RA response elements (RAREs) found within the promotor region.
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2.3.2 DX314 INDEPENDENTLY MITIGATES RHE BARRIER
DISRUPTION
We measured the transepithelial electrical resistance (TEER) of RHE from the first
series of experiments as a functional measure of barrier integrity. To account for the
inherent variability across experiments and keratinocyte sources, the results of each
independent run were pooled and normalized to their respective controls. We observed a
significant decrease in TEER by atRA (Figure 2.6). Talarozole and liarozole alone showed
no significant effect on TEER, while cotreatment with nanomolar atRA resulted in a
significant decrease. Surprisingly, 1000nM DX314 showed an increase in TEER and there

Figure 2.6: Normalized TEER of RHE treated with atRA, RAMBAs.
Experiment 1 (groups 1 and 2) RHE following 4-day treatment with atRA or
RAMBAs with, or without, atRA cotreatment. Data includes pooled results of 9
independent runs performed during experiment 1. Post-treatment TEER values
were normalized to the control RHEs within each run. Graph shows Tukey’s
boxplot with outliers. Sample sizes (n) are shown above x-axis. Significance vs
the vehicle control determined by one-way ANOVA with Dunnett’s correction for
multiple comparisons. *p≤0.05; **p≤0.01; ***p≤0.001
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was no observed decrease in TEER when cotreated with atRA. This is despite our gene
expression studies indicating a robust potentiation of atRA effects. TEER was measured
again in the second series of experiments (Figure 2.7a), however, we found that the D11
(post-treatment) TEER in all groups, apart from 100nM atRA, exceeded the accuracy
threshold of the instrument (accurate at ≤10,000Ω), so any differences could not be
resolved. Despite the instrument limitation invalidating any conclusive analysis of the
results, we believe the initial trends observed on D9 were consistent with, and certainly do
not contradict, the observations of the first experiment.
Assessment of TEWL also proved problematic in this study. The experiment was
performed twice, and the results combined for analysis. Although it initially appeared that
DX314 treated RHE may have slightly reduced the average TEWL (Figure 2.7b), the
experiment as performed did not find any statistically significant differences and
conclusions could not be drawn.
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Figure 2.7: TEER and TEWL of RHE

a

treated with atRA, DX314. (a) Raw TEER
of RHE (experiment 2, group 3) following
treatment with atRA or DX314 with, or
without atRA cotreatment. Raw TEER of
D7 (blue, before treatment), D9 (red, 2 days
of treatment), and D11 (green, 4 days of
treatment) are shown.

Due to TEER

measurements exceeding the accuracy
limits of the instrument (rated at 10,000Ω,

b

dotted line) in most samples, a proper
analysis could not be performed. Bars show
mean±SD. (b) Corrected TEWL values
from two runs of RHE (experiment 2, group
4) treated with atRA or DX314 with, and
without, atRA cotreatment. Black bar
indicates mean, each point represents a
single RHE. One-way ANOVA with
Dunnett’s
comparisons
differences

correction
showed
between

for
no
control

multiple
significant
and

any

treatment.

Morphologically, atRA treated RHE showed a distinct disruption of normal tissue
structure (Figure 2.8). Observed changes include a near total loss of the dark, FLGcontaining, keratohyalin granules (KG) typically found in the stratum granulosum (SG), a
shift in the stratum basale (SB) keratinocytes from a typical columnar appearance to a more
rounded appearance (more closely resembling SS keratinocytes), a less nucleated stratum
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spinosum (SS), and an overall unhealthy appearance. RHE treated with liarozole or
talarozole alone showed no major histological changes, but RHE cotreated with nanomolar
atRA resemble the RHE treated with high dose atRA. Similarly, DX314 causes no major
changes in morphology when dosed alone, but unlike the other RAMBAs, we observed
minimal disruption of normal morphology with atRA cotreatment (intact SG/KG,
columnar SB keratinocytes, generally healthy tissue appearance). A replication study of
these effects on RHE morphology by atRA and DX314 showed the same results (Figure
2.9). When we consider the gene expression profile showing a strong potentiation of low
dose atRA by DX314, this finding seems to suggest that DX314 displays a subtle protective
effect on epidermal integrity and may be able to mitigate the more aggressive adverse
effects of atRA treatment.

58

Figure 2.8: Morphological changes in RHE treated with atRA, RAMBAs. RHE
(experiment 1, group 2) morphology changes after 4-day treatment. 6µm sections
were stained with H/E. Control RHE consists of columnar keratinocytes in the
stratum basale (SB, bottom layer), flattened cells in the stratum spinosum (SS,
second layer), a thick stratum granulosum (SG, third layer) with many keratohyalin
granules (KG, stain as a dark grainy texture within SG), and a relatively thin but
tightly packed stratum corneum (SC, upper layer). Scale bars = 20µm.
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a uniform sample population. Scale bar = 50µm

to confirm morphological effects. Note that adjacent tissues in this experiment are not paired and replicates can be considered

Figure 2.9: Replicate histology of healthy RHE treated with atRA, DX314. Images from a replication of the initial study

The epidermal differentiation complex (EDC) is a cluster of genes, found on human
locus 1q21, that are essential for epidermal differentiation 149. We mapped the expression
of these genes, as well as some known EDC gene expression regulators, to the RNAseq
data we collected (Figure 2.10). Overall, the expression patterns appear to be consistent
with observations of other retinoid-responsive genes previously discussed. However, we
did observe that the expression of many genes in the cornified envelope precursor family
were not affected by DX314 + atRA treatment despite a dramatic downregulation by high
dose atRA. We speculate that a preservation of cornified envelope protein expression may
be a factor contributing to the increase in TEER observed in DX314 treated RHE.
Investigation into whether this observation directly contributes to the barrier effects we
have shown should considered in future studies of DX314.
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Figure 2.10: Fold-change in expression
of epidermal differentiation complex
(EDC) genes. RNAseq results from RHE
(experiment 2, group 3) treated for 4 days
with atRA, DX314. Adjacent column
(left side) separates genes by the three
major EDC groups (light blue, pink,
purple). We also show expression of
several known EDC regulators (green).
Dark grey cells indicate a lack of
statistical significance, while all colored
cells

are

considered

statistically

significant changes in expression (FDR ≤
0.05).
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2.3.3 PATHWAY AND UPSTREAM REGULATOR ANALYSIS OF
DX314 AND atRA
Data from the RNAseq study was then ingested into Qiagen’s Ingenuity Pathways
Analysis (IPA) software for in silico canonical pathway and upstream regulator analysis.
We elected to use significance cutoffs of FDR ≤ 0.05 and fold-changes ≥ 1.5 or ≤ -1.5 to
limit the number of genes used in the analysis. These cutoffs resulted in 1360, 5480, 169,
and 3015 differentially expressed genes being considered for analysis of 1nM atRA,
100nM atRA, 1000nM DX314, and 1000nM DX314 + 1nM atRA, respectively. As per the
recommendations, the pathway regulator predictions by IPA were considered significant if
the Fisher’s exact p-value was ≤ 0.05, and the z-score was ≥ 2.0 (predicted activation) or ≤
-2.0 (predicted inhibition).
The results of IPA’s upstream regulator analysis were filtered to only include
“genes, RNA, proteins, and endogenous chemicals”, then sorted by overall |z-score| (Figure
2.11, left). As expected, the regulator with largest predicted activation was atRA
(tretinoin), and the predicted activation scores displayed a pattern consistent with a
potentiation of low-dose atRA by DX314 (i.e. there is no significant activation by DX314
alone, while DX314 with atRA results in a score exceeding that of atRA alone). Of the top
20 scoring regulators, only three weakly displayed any predicted activity by DX314 alone
suggesting minimal effects by DX314 in the absence of atRA.
Canonical pathway analysis (Figure 2.11, right) found the overall most activated
(“Integrin Signaling”) and inhibited (“RhoGDI Signaling”) pathways both display
activation score patterns which suggest a potentiation of low-dose atRA by DX314.
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Diagrams of these two signaling pathways, as well as the “RAR activation” pathway for
each treatment can be found in the supplemental data (Supplemental Figure 1,
Supplemental Figure 2, Supplemental Figure 3). Only a single pathway (“Neuroprotective
Role of THOP1 in Alzheimer’s Disease”) was found to be modulated by DX314 alone,
however the effect was weak with the z-score (= 2.0) just meeting the recommended cutoff
threshold for significance.

Figure 2.11: Pathway analysis of RNAseq profiles. (left) The top 20 highest scoring
upstream regulators (including; genes, RNA, proteins, and endogenous chemicals) as
predicted by IPA. (right) The top 20 highest scoring canonical pathways predicted by
IPA. A positive z-score (orange) predicts activation, while a negative z-score (blue)
predicts inhibition. A black dot indicates scores that did not meet the threshold for
significance (|z-score| ≥ 2).
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2.4 DISCUSSION
Retinoids are well-established therapeutics for the treatment of many skin
diseases43,60,64. Despite their efficacy, their use can often lead to adverse reactions in
patients due to undesirable activity exacerbated by autoinduction of its metabolism and
tolerance58,150. A strategy involving the use of RAMBAs, which target the RA-inactivating
CYP26 enzyme, was developed to address these issues. Although preclinical studies and
clinical trials did show their potential in treating certain skin disorders 41,88,112,121,151,89–91,107–
111

, first-generation RAMBAs such as liarozole, have not progressed past clinical trials,

likely due to off-target activity106. Consequently, there remains a strong interest in highly
selective RAMBAs, with low risk of adverse events, that could address the downsides of
current treatments.
Here, we show our novel CYP26B1-selective RAMBA, DX314, can potentiate the
effects of low-dose atRA in healthy RHE. We investigated the effects of atRA on several
retinoid-responsive genes compared to DX314 or liarozole, when treated with, or without
atRA at a nanomolar concentration (Figure 2.2). We confirmed an increase in HBEGF,
CYP26A1, and CYP26B1 mRNA expression by atRA. Although the effect on IVL
expression was less robust, we did see a significant increase in IVL expression by atRA at
a dose of 100nM. Our experiments also show that, when used alone, neither RAMBA had
a significant effect on the expression of these genes at any dose. DX314 was able to
significantly potentiate atRA’s effects on HBEGF, IVL, CYP26A1, and CYP26B1
expression. Liarozole with atRA was only able to significantly alter the expression of
HBEGF and CYP26A1. Immunostaining confirms the effects of DX314 and atRA on IVL
65

localization (Figure 2.3), however CYP26A1 and CYP26B1 staining (Figure 2.4) was
found to be irregular and not reflect mRNA expression. Because this anomaly has been
previously reported in in vivo and in vitro studies of healthy and ichthyotic skin, we do not
believe it conflicts with our conclusions111,138,139.
In the initial experiments, replicates were done using RHE grown from different
donors. This study design ensured that any observed effects must be robust enough not be
overly sensitive to inter-individual differences, however, this also resulted in large
variances across independent experimental runs.
For the design of the second series of experiments we chose to study DX314 and
atRA in RHE using RNAseq and a single, independent source of primary keratinocytes for
all replicates. This experiment confirmed the expression effects of atRA, the lack of effect
with DX314 alone, and the atRA potentiating effect of DX314 on HBEGF, IVL, CYP26A1
and CYP26B1 expression (Figure 2.5). This experiment also allowed us to investigate the
effects on many other genes of interest of which the overwhelming majority supported the
atRA potentiation hypothesis. We observed this pattern in genes regulated by both direct
(RARE-containing promotor), and indirect RA pathways. Based on these results, we
conclude that DX314 can potentiate the effects of nanomolar atRA by inhibiting the
metabolism of RA.
TEER is a useful method of assessing epidermal barrier integrity in vitro.
Surprisingly, we found that RHE treated with 1000nM DX314 displayed a significant
increase in TEER compared to control, and unlike liarozole or talarozole, no decrease in
TEER when cotreated with low-dose atRA (Figure 2.5). Despite atRA robustly decreasing
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TEER, and DX314 otherwise appearing to potentiate the gene expression effects of atRA,
we did not observe deterioration of barrier function in RHE dosed with a cotreatment of
DX314 and atRA. Replication studies of these TEER effects were inconclusive due to
instrument limitations (Figure 2.7a), however, we believe the trends observed in the data
show a pattern consistent with the previous observations. Morphologically, DX314 treated
RHE appear to show significantly less disruption of the SG and KGs, and display an overall
healthy appearance compared to high dose atRA or liarozole treated groups (Figure 2.8,
Figure 2.9). We also found minimal changes in the expression of many corneal layer
precursor transcripts within the EDC (Figure 2.10), despite a large decrease in expression
by high-dose atRA, and most retinoid-responsive genes showing DX314 potentiating
atRA’s effects on gene expression. Whether or not DX314 does protect the skin barrier,
while also retaining the therapeutic benefits of retinoids, remains to be seen and we cannot
make a conclusive statement based solely on this study, however, we believe the
observations made certainly merit further investigation. Additional in vitro and in vivo
studies utilizing alternative measures of barrier integrity and function may provide
additional insight into these unique observations.
Finally, we present the activity of upstream regulators (Figure 2.11, left) and
canonical pathways (Figure 2.11, right) as predicted by IPA software. The top scoring
upstream regulator was atRA (i.e. tretinoin) which showed an activation z-score of 5.04
and 6.90 for 1 and 100nM atRA, respectively. DX314 alone scored below the significance
threshold at 1.70, but when cotreated with 1nM atRA scored 7.94. This result strongly
suggests DX314 alone does not significantly affect known RA pathways, but potently
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potentiates the effects of atRA in cotreated conditions. 16 of the top 20 scoring upstream
regulators, and 14 of the top 20 scoring canonical pathways showed DX314 with low-dose
atRA as having an absolute z-score larger than low-dose atRA alone. Overall, these results,
in conjunction with the previously discussed data, provide further evidence of DX314’s
ability to potentiate the effects of nanomolar atRA.
We conclude that the results presented in this study show strong evidence that
DX314, which is known to inhibit the RA-metabolizing enzyme CYP26B1, potentiates the
effects of atRA in healthy RHE. We also show compelling evidence that DX314 may
protect from epidermal barrier disruption by retinoids, and strongly believe these
observations merit further study.
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3. DX314 AS A POTENTIAL THERAPEUTIC IN
KERATINIZATION DISORDERS
3.1 INTRODUCTION
Keratinization disorders refer to a class of skin disorders which induce a disruption
of normal keratinocyte differentiation (keratinization) and resulting in abnormal skin
development and function. In this study, we expand upon our previous research confirming
DX314 will potentiate the effects of low-dose atRA, with minimal undesirable off-target
activity. To determine if these effects will translate from healthy keratinocytes to the
potentially unique responses of diseased keratinocytes, we investigated DX314 in two
keratinization disorders which have an established clinical history of effective treatment
by retinoids.
In the first series of experiments, we grew RHE using keratinocytes donated by a
patient with Darier’s disease (DD). Although RAMBAs have not specifically been
investigated or used for treatment of this disease, retinoids, particularly 13-cis-RA, have
been used as an effective treatment in DD patients47–49. If the advantages of RAMBAs can
be shown to be as effective as retinoids in DD, implementing their use may improve
patients’ outcomes and provide more treatment options to their physicians. For the second
series of experiments, we studied the effects of DX314 on keratinocytes donated by
congenital ichthyosis patients. The subtypes investigated in this study include two
recessive x-linked ichthyosis (RXLI) donors (herein referred to as RXLI-1653 and RXLI1658), and one lamellar ichthyosis (LI) donor (LI-173).
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3.1 METHODS
3.1.1 PRIMARY HUMAN KERATINOCYTES
Darier’s disease keratinocytes (DARK1) from a male child were donated to the
project by our collaborator Dr. Yves Poumay at the University of Namur, Belgium.
Recessive x-linked ichthyosis (RXLI) and lamellar ichthyosis (LI) keratinocytes were
provided by Dr. Amy Paller at Northwestern University, Illinois. Keratinocytes from three
ichthyosis patient donors were used in this study: RXLI-1653 (29yo, male), RXLI-1658
(13yo, male), and LI-173 (details not provided).

3.1.2 CELL CULTURE
Refer to Section 2.2.2.

3.1.2.1 MONOLAYER AUTOCRINE KERATINOCYTES
Culture of monolayer RXLI keratinocytes was performed by the Paller lab and is
adapted from a method described by Poumay et al.123. In short, 25,000-50,000
keratinocytes (prepared as described in Section 2.2.2) are seeded in 6-well cell culture
plates containing 2mL of Epilife Complete and placed in a 37°C, 5% CO 2, humidified
incubator. The media is changed every two days until ~60% confluent, at which point the
media is replaced with Epilife Autocrine (Epilife media, 0.5% P/S, 0.5µM hydrocortisone,
240µM L-histidine, 750µM L-isoleucine, 90µM L-methionine, 90µM L-phenylalanine,
45µM L-tryptophan, 75µM L-tyrosine), which does not contain any HKGS, for the
remainder of the experiment. This autocrine formula allows for the investigation of
epidermal differentiation markers, which can otherwise be affected by growth factors
present in non-autocrine media, using monolayer keratinocyte cultures. The keratinocytes
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continue to proliferate in autocrine conditions, and the media changed every two days, until
100% confluent. Once all the wells in an experimental group reach confluence, treatments
are added to fresh Epilife Autocrine (final concentration of 0.1% DMSO as vehicle),
applied to each well, and allowed to incubate for 20hrs. After the 20hr treatment, the media
is aspirated from each well and 500µL of TRIzol (Thermo, 15596-018) is immediately
added. The cells are homogenized, and the lysate is flash frozen at -80°C until shipped to
us on dry ice for RNA isolation.

3.1.2.2 RECONSTRUCTED HUMAN EPIDERMIS
Refer to Section 2.2.2.1.

3.1.2.3 ORGANOTYPIC RAFTS
Organotypic rafts were grown by collaborators at the Paller Lab (Northwestern
University) using a previously described protocol 152. The protocol here is described per raft
so all components were scaled according to the number of rafts within each experiment.
For each raft, 4e5 J2-3T3 fibroblasts are suspended in 150µL of 10x reconstitution buffer
(22µg/mL NaHCO3, 46µg/mL HEPES in 0.05N NaOH then 0.2µm sterile filtered). On
ice, 150µL of 10x DMEM is then added, followed by 6mg of rat tail collagen I (BD,
354249), which is rocked gently until color changes to yellow indicating the solution is
acidic. We then add 0.5N NaOH until the pH becomes neutral and the solution is brought
up to 1.5mL (per raft) with sterile ddH2O. 1.5mL of the collagen suspension is added to a
well of a 12-well plate and placed in a 37°C incubator for 30min to polymerize, after which
an additional 3mL of media is added to the top of each plug. This is then incubated at 37°C
for at least 24hrs before keratinocytes can be added. After 1-4 days, media is removed from
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each plug and replaced with 1mL of E media [180µM adenine (Signa, A2786), 5µg/mL
human recombinant insulin (VWR, 91077C), 5µg/mL human apo-transferrin (Sigma,
T1147), 5µg/mL triiodothyronine T3 (Sigma, T6397), 0.25µg/mL Amphotericin B
(Cellgro, 30003CF), 4nM L-glutamine (Sigma, G7513), 0.4µg/mL hydrocortisone (Sigma,
H0888), 10ng/mL Cholera toxin (Sigma, C8052), 5% FBS (Fisher, SV30014.03), in 1:1
mix of DMEM HG (Sigma, D5671): DMEM/F-12 (Sigma, D6421)] supplemented with
5ng/mL EGF. For each raft, suspend 6e5 keratinocytes in 1mL E media + 5ng/mL EGF
and add this suspension to the top of a collagen plug. The media is refreshed after 24hrs.
After two days, a sterile spatula is used to transfer each raft to the top of a sterile metal grid
in a 60mm plate. Enough media is added so that only the bottom of the raft is submerged,
and an air-tissue interface is established on the surface (~4-5mL). The rafts are placed in
an incubator and media is maintained every two days until the experiment is complete. As
with the RHE, treatments (0.1% DMSO vehicle) are done over four days and refreshed
after two days. Rafts intended for RNA isolation are then lysed in 500µL TRIzol and stored
at -80°C until shipped to us on dry ice for RNA isolation.

3.1.3 TEWL
Refer to Section 2.2.3.

3.1.4 TEER
Refer to Section 2.2.4.

3.1.5 HISTOLOGY & IMMUNOSTAINING
Refer to Section 2.2.5.
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3.1.6 DIFFERENTIAL GENE EXPRESSION
3.1.6.1 RNA ISOLATION
Isolation of RNA from RHE groups was performed as described in Section 2.2.6.1.
RNA obtained from monolayer and organotypic raft cultures were isolated using
TRIzol (phenol-chloroform extraction) as described by the manufacturer. Variations from
the standard protocol include chilling the sample following the addition of isopropanol to
encourage nucleic acid precipitation, and the addition of a second chilled 75% ethanol wash
prior to drying the pellet, which greatly improved consistency in RNA purity.

3.1.6.2 RT QPCR
DD RHE study was performed as described above (Section 3.1.6.2) Remaining
groups in this study were done with several variations from the previously described
method which are described here:
A 10µL reverse transcription was done with 100-200ng of template RNA using
qScript cDNA Supermix (QuantaBio, 95048) with the following incubations: 5min 25°C,
30min 42°C, 5min 85°C. The cDNA was then diluted 1:10 with water and 2µL was added
to a 10µL real-time qPCR reaction, which used PerfeCTa SYBR Green Supermix, LowROX (QuantaBio, 95056) on a Stratagene Mx3005P (Agilent Technologies) or CFX384
(Bio-Rad). Program is as follows (40 cycles): 30sec 95°C, 60sec 60°C, 60sec 72°C.
Statistical analysis was done by one-way ANOVA with Dunnett’s correction for multiple
comparisons on the standardized (DD RHE), or raw dCt (remaining experimental groups),
values using GraphPad Prism 6. Primers can be found above (Table 2.3).
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3.2 RESULTS
3.2.1 DX314 IN DARIER’S DISEASE RHE
DD RHE were investigated by the same experimental methodologies used for the
previously described healthy RHE studies (Section 0). As expected, atRA treatment
produced an increase in HBEGF and CYP26A1 gene expression, and a decrease in KRT10
expression (Figure 3.1). The potent RAMBA talarozole significantly potentiated the effects
of all genes analyzed, at all doses studied. DX314 was able to significantly potentiate
effects of atRA on both KRT10 and CYP26A1 expression. However, despite indicating a
higher average fold-change in HBEGF gene expression, RHE treated by DX314 with lowdose atRA did not reach the predefined threshold for statistical significance. Due to the
precious nature of the DD keratinocytes, we were limited in the number of replicates which
could be used for qPCR analysis which resulted in low statistical power. This small sample
size likely explains the lack of a statistically significant change in HBEGF expression
despite a significant modulation of this gene observed in our previous studies.
Histological analysis shows atRA inducing robust morphological changes in DD
RHE (Figure 3.2, left column) which reflected those seen in healthy RHE (Figure 2.8).
RHE treated with atRA showed a dramatic loss of the SB (and KGs typically contained
within), denucleation and flattening of SS keratinocytes, and an overall unhealthy
appearance. When treated alone, DX314 and talarozole showed no major morphological
changes, however addition of nanomolar atRA shifted the appearance, most notably the
SG/KG, to more closely resemble high dose atRA. Visualization of FLG localization
(Figure 3.2, middle left column) shows, as we would expect, expression largely isolated to
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the granular and corneal layers of the epidermis. Treatment with atRA results in a decrease
in FLG staining relative to control. Talarozole alone displays similar FLG staining to
control, while talarozole with atRA shows expression levels resembling high dose atRA.
Conversely, DX314 appears to display significantly increased FLG relative to control, an
observation which may contribute to the increase in TEER seen in the DX314-treated RHE
from our previous study (Section 2.3.2). DX314 with 1nM atRA shows FLG levels
mimicking those of high dose atRA which suggests DX314 is potentiating the effect of
atRA on FLG staining. KRT14, a cytokeratin typically isolated to basal keratinocytes,
shows decreased staining following atRA treatment, no significant change following
treatment by DX314 or talarozole, and diminished expression when RAMBAs are
cotreated with atRA (Figure 3.2, middle column). Finally, KRT10, a commonly used
marker of epidermal differentiation typically localized within the suprabasal epidermis,
shows delayed expression in atRA treated RHE. This seen as an apparent migration of
KRT10 staining away from the lower layers, and more isolated to the apical layers of the
epidermis (Figure 3.2, middle right column). When treated alone, the RAMBAs studied
here show no change in KRT10 localization relative to control, however, when cotreated
with low dose atRA, staining is diminished in the lower layers and only seen in the more
apical layers. Overall, this study of DD RHE histology presents compelling evidence that
DX314 potentiates the effects atRA and does so in a manner comparable to the well-studied
RAMBA talarozole.
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Figure 3.1: Gene expression in DD RHE treated with atRA, RAMBAs.
Differential expression of HBEGF (a-c), KRT10 (d-f), and CYP26A1 (g-i)
transcripts after 4-day treatment with atRA or RAMBAs, with (grey bars), and
without (white bars), 1nM atRA. Solid line shows control and dotted line shows
1nM atRA RHE. Significant changes vs control determined by one-way
ANOVA with Dunnett’s multiple comparisons correction on autoscaled values.
*p≤0.05; **p≤0.01; ***p≤0.001. Graphs show mean ± 95% CI. n = 3 per
treatment. Note: CYP26A1 control showed no detectible signal after 40 cycles
so a target Ct of 40 was assigned to any undetected samples.
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left side of tissue shows cellular nuclei (blue) stain overlaid with target. Black scale bar = 20µm, white scale bar = 50 µm).

KRT10 (middle right), and negative controls (right) are shown here. Left side of the tissue shows target protein (green) alone,

Figure 3.2: Histology of Darier's disease RHE treated with atRA, RAMBAs. HE (left), FLG (middle left), KRT14 (middle),

3.2.2 DX314 IN ICHTHYOTIC KERATINOCYTE CULTURES AND
3D EPIDERMIS
Recessive X-linked ichthyosis (RXLI-1658) patient keratinocytes were grown in
monolayer cultures and differentiated under autocrine conditions. Cultures were treated for
20hrs with atRA or RAMBAs (DX314 or liarozole) with, and without, atRA cotreatment
before RNA was extracted for subsequent RT-qPCR. RXLI-1658 monolayer cultures
showed DX314 (100 and 1000nM doses) and liarozole (all doses) can potentiate the effect
of 1nM atRA on the expression HBEGF and CYP26A1 (Figure 3.3) transcripts. DX314
only appeared to potentiate atRA’s effect on KRT10 and FLG gene expression at the
highest doses tested, however, we also found that 10nM DX314 alone increases their
expression. This subtle, but significant, increase likely lessens the decrease in expression
we would expect when inhibiting atRA metabolism. This may explain why only the highest
DX314 dose displayed gene expression changes exceeding those of 1nM atRA alone.
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*p≤0.05;

**p≤0.01;

***p≤0.001. n = 3. Bars show
mean ± 95% CI.

To investigate how DX314 would perform in RXLI organotypic skin models, rafts
were grown using RXLI-1653 keratinocytes which were given a 4-day drug treatment
before RT-qPCR was performed on the isolated RNA. Consistently with our previous
studies, atRA induced an increase in HBEGF and CYP26A1 gene expression (Figure 3.4).
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Contrarily to our previous observations, DX314 and liarozole appeared to slightly increase
HBEGF gene expression in the absence of atRA. This unexpected effect was also seen on
the expression of CYP26A1 transcripts when the rafts were treated with liarozole, but not
DX314. However, when cotreated with low dose atRA, an unmistakable potentiating effect
was still seen by both RAMBAs in both genes.

Figure 3.4: Gene expression in RXLI-1653 organotypic rafts. Rafts
grown with keratinocytes from an RXLI patient were treated for 4-days.
Expression of HBEGF and CYP26A1 genes was measured by RT-qPCR.
Significant expression changes vs control was determined by one-way
ANOVA with Dunnett’s correction for multiple comparisons on dCt
values. *p≤0.05; **p≤0.01; ***p≤0.001. n = 3 per treatment. Bars show
mean ± 95% CI.
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Our final study of DX314 in diseased keratinocytes was performed in RHE grown
with lamellar ichthyotic (LI) donor keratinocytes. We analyzed the expression of several
of the retinoid-responsive genes we had previously studied. As expected, CYP26A1,
CYP26B1, HBEGF, and KRT10 transcripts displayed a change in expression by atRA
(Figure 3.5). In agreement with our immunolabeling of DD RHE (Figure 3.2), atRA
treatment decreased KRT14 mRNA expression in the LI RHE. Stimulated by retinoic acid6 (STRA6), a gene with a strong RARE-mediated response to RA treatment, also saw a
robust increase in expression by atRA. Expression of TGM-1, a transglutaminase
responsible for cross-linking the structural proteins of the cornified envelope, was
decreased by atRA. In all the genes investigated here, 1000nM DX314 alone had no effect
on gene expression, however, unlike our previous studies, only CYP26A1 and STRA6
showed expression patterns suggesting a potentiation of low dose atRA by DX314. The
effects of DX314 with lose-dose atRA do not appear to be significantly different from low
dose atRA alone for CYP26B1, HBEGF, TGM1 or KRT14 expression.
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Figure 3.5: qPCR of LI-173
RHE

treated

with

DX314,

atRA. RHE were treated for 4
days before measuring relative
changes in expression of several
genes of interest by RT-qPCR.
Significant expression changes vs
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correction
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for
on
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values.

*p≤0.05; **p≤0.01; ***p≤0.001.
n = 3 per treatment. Bars show
mean ± 95% CI.

In the same study of LI RHE, we concurrently investigated the effect treatments on
TEER and TEWL to their effects on epidermal barrier integrity. As we originally
discovered in healthy RHE (Figure 2.6), we see atRA decreased TEER, while DX314
independently increased TEER and mitigates atRA’s effect on TEER when cotreated
(Figure 3.6a). As a secondary measure of barrier function, we also measured the TEWL of
the RHE following the 4-day treatment. In support of our TEER observations, we find
atRA induces a robust effect on this measure of barrier function, however, we did not find
that DX314 had any significant effect on TEWL, nor did it mitigate the effects of low-dose
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atRA in cotreatment conditions (Figure 3.6b). Finally, since we simultaneously measured
both TEER and TEWL on the same RHE, we analyzed the two metrics together to see if
there exists a correlation between the two measures of barrier function. We show that,
within the range of the TEER and TEWL values of these RHE, there exists an inverse linear
relationship between the two, and each treatment tends to cluster with its replicates (Figure
3.6c).

Figure 3.6: TEER and TEWL
of

LI

RHE

DX314,

treated
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Raw,
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the

linear

correlation

between the two (c) following
treatment. Significant changes
vs control determined by oneway ANOVA with Dunnett’s
correction
comparisons.

for

multiple
*p≤0.05;

**p≤0.01; ***p≤0.001. n = 5 per
treatment.
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Investigating the treatment effects on RHE tissue morphology shows LI RHE
reacting to atRA and DX314 in a manner nearly identical to the changes seen in our studies
of healthy and DD RHE. High dose atRA leads to a significant reduction in SG thickness
and KG presence and displays an overall unhealthy appearance (Figure 3.7). RHE treated
with DX314 with, and without low dose atRA, show minimal histological changes relative
to control, although there does appear to be a slightly more continuous presence of KG
across the SG.

Figure 3.7: Morphology of LI RHE treated with DX314, atRA. HE stained LI
RHE treated for 4 days with atRA or DX314, with, and without low dose atRA.
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3.3 DISCUSSION
Darier’s disease (DD) and congenital ichthyosis are keratinization disorders with a
well-established history of effective treatment by retinoid-based therapies41,45,47,48,50,88. As
previously discussed, excessive retinoid use often results in adverse effects and drug
tolerance despite their proven efficacy. In this series of experiments, we expand upon the
work done in our previous studies which show DX314’s effects in healthy in vitro RHE.
With the help of two of our collaborators, we investigated whether DX314 can also mimic
the desirable effects of proven therapies in diseased keratinocytes.
In the DD portion of this study, atRA treatment resulted in an increase (HBEGF,
CYP26A1), or decrease (KRT10), in gene expression consistent with our hypothesis
(Figure 3.1). DX314, as well as the potent RAMBA talarozole, were able to significantly
potentiate the effects of a low dose atRA cotreatment on the gene expression of KRT10
and CYP26A1. Statistically speaking, the expression of HBEGF was only significantly
modified by talarozole, however, we do not believe the effect of DX314 should be
discounted despite the lack of statistical significance. Due to the rarity of DD, sourcing
additional donors is quite difficult, and the necessarily low number of cellular passages
required for quality RHE limited the number of replicates possible. These limitations led
this experiment to have inadequate statistical power considering the relatively small effect
size of the treatments on HBEGF expression. Considering the mean change in HBEGF
expression in this experiment is consistent with expectations and our multiple previous
studies showing DX314 potentiating the effect of atRA its expression, we suggest these
results are still in support of our overarching hypothesis.
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Histological imaging shows
DD

RHE

having

distinct

morphological differences compared
to healthy RHE (Figure 3.8). We can
see that DD RHE lack the columnar
keratinocytes characteristic of the SB,
have

a

greatly

diminished

SG,

Figure 3.8: RHE grown with healthy (top) or

increased acantholysis (intercellular DD (bottom) keratinocytes. Red circle shows a
corps rond (round body) keratinocyte, commonly
gaps due to poor cell-cell adhesion),
found in DD epidermis. Scale bar = 20µm.
and the presence of corps rond
(abnormal keratinocyte, red circle) which are characteristic traits of DD epidermis in vivo45.
This study found that DD RHE morphology is affected by the treatments in a nearly
identical manner to our previous studies of healthy RHE. Treatment with atRA caused a
loss of the SG, a reduction in epidermal thickness, and denucleation of the SS (Figure 3.2,
left column). Both DX314 and talarozole show no significant histological effect alone,
however, low-dose atRA cotreatment results in the tissue morphology mimicking highdose atRA treated RHE.
As we would expect, FLG staining correlated with the loss of SG by atRA, and as
such, also supports a potentiation of atRA by RAMBAs, however, we also found that
DX314 appears to independently increase the prevalence of FLG (Figure 3.2, middle left
column). We did not initially expect this, however FLG’s critical role in tight junction
formation within the SG may contribute to, and partially explain, DX314’s previously
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described ability to increase TEER (Figure 2.7, Figure 3.6). Although we did not
investigate KRT14 gene expression in DD RHE, we know it to be controlled by RAREs 153
and our previous study showed KRT14 downregulated by atRA in healthy RHE (Figure
2.5). For these reasons, we investigated KRT14 localization in DD RHE and found that
atRA does induce a decrease in KRT14 staining, RAMBAs alone show no significant
effect, and RAMBAs cotreated with atRA show a decrease in staining (Figure 3.2, middle
column). KRT10 is not directly controlled by RAR as it does not contain a RARE
promotor, however, its expression is well established as a marker of keratinocyte
differentiation and highly sensitive to retinoid treatment. We found KRT10 localization in
the control and RAMBA alone groups to begin just above the basal layer keratinocytes and
continue into the upper layers of the epidermis (Figure 3.2, middle right column). When
treated with atRA, or RAMBAs with low-dose atRA, we observe a shift in KRT10
localization to only the upper layers of the epidermis with significantly reduced staining in
the SS. Additionally, this reduction in KRT10 staining by the treatments is consistent with
the observed decrease in KRT10 mRNA expression (Figure 3.1). These studies show the
effects observed in healthy RHE are translatable to DD RHE, and that DX314 also
potentiates low dose atRA in this disease. Together this suggests DX314 may have
potential as an effective treatment strategy for Darier’s disease patients.
In the congenital ichthyosis portion of this study, we investigated the effects of
atRA and DX314 in various in vitro experiments using keratinocytes donated by two
recessive X-linked ichthyosis (RXLI) patients and a lamellar ichthyosis (LI) patient.
Investigation of gene expression changes after a 20hr treatment of differentiated monolayer
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RXLI-1658 keratinocytes shows DX314, as well as liarozole, potentiating the effects of
low-dose atRA on HBEGF, KRT10, CYP26A1, and FLG gene expression (Figure 3.3).
We did, however, only observe a significant potentiation of HBEGF and CYP26A1
expression at 100nM and 1000nM DX314, while KRT10 and FLG expression were only
potentiated with a 1000nM dose. Surprisingly, we also found 1000nM DX314 and 1000nM
liarozole independently increasing HBEGF and CYP26A1 expression in the absence of
atRA cotreatment. This observation is inconsistent with our previous studies which did not
see any such effect by RAMBAs alone. It is possible that this is the result of a unique
property of monolayer cultures, which is not seen in 3D epidermis; however, we believe it
is more likely that a sub-nanomolar concentration of atRA, or a RA precursor, was present
in the media of those samples, and was subsequently potentiated by each RAMBA. We
also see that 10nM DX314 appears to increase KRT10 and FLG gene expression. Although
this increase in structural proteins may be partially contribute to the increase in barrier
function previously described, we did not observe an effect on these genes in DD RHE, or
in the previous RNAseq study of healthy RHE, so it is likely that this effect is specific to
monolayer cultures and does not translate to the 3D epidermis models which better reflect
in vivo conditions.
Our investigation of RXLI-1653 organotypic rafts also show HBEGF and
CYP26A1 gene expression was increased by atRA treatment (Figure 3.4). We also show
that both DX314 and liarozole at 1000nM potentiate the effects of low dose atRA on these
genes together reinforcing our hypothesis. Despite this, we again observe that 1000nM
DX314 has a subtle effect on HBEGF expression, while 1000nM liarozole shows a robust
88

effect on both genes in the absence of atRA. These RXLI rafts, as well as the previous
RXLI monolayer studies, were performed in unison, so it is possible that the discrepancies
of both can be explained by a presence of retinoids in the media, as previously suggested.
Replication of these studies was not possible within the timeframe of this dissertation;
however, additional experiments have already begun and should help determine if this is
indeed a possibility.
Finally, we investigated the gene expression and barrier effects of DX314 in LI173 RHE. As predicted, gene expression analysis shows an effect by atRA, and no effect
by DX314 alone on all genes investigated (Figure 3.5). We confirm DX314 potentiates the
effects of low-dose atRA on the RARE-promoted CYP26A1 and STRA6 genes, however,
unlike our previous studies, DX314 was not able to significantly affect the expression of
the other genes presented any more than low-dose atRA alone. We are unsure as to why
these genes were not potentiated by DX314 as we would have expected. It is possible that
the genetic differences of this LI donor result in truncated effects relative to the other
donors, however, in that case we would expect to be see this reflected in RHE treated with
atRA alone as well. Another possibility is that RA metabolism in this LI donor has an
increased propensity to undergo alternative, compensatory pathways and therefor the
specific inhibition of CYP26 does not reduce the inactivation RA enough to affect the
expression genes less sensitive to modulation by RA. This may explain why we see the
expected effects in CYP26A1 and STRA6 expression, but not the others. Finally, this lack
of agreement with previous studies may be significantly more complicated than a single
variable can account for and it may be the result of a complicated series of genomic and
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non-genomic effects specific to this donor. In any case, we do not believe that this lack of
RA potentiation in these specific cases invalidates our general hypothesis. It may merely
suggest that, like many other drugs, the efficacy of RAMBAs are subject to interindividual
variability and situational differences, meaning they may not universally work in all
patients and disorders.
To further gather evidence of the barrier protecting effect of DX314 first observed
in our studies of healthy RHE (Section 2.3.2), we measured post-treatment transepithelial
electrical resistance (TEER) and trans-epidermal water loss (TEWL). We confirm atRA
decreases, while DX314 independently increases TEER, suggesting a respective decrease
and increase in barrier function, in LI RHE (Figure 3.6a).
We simultaneously investigated the effects treatments have on TEWL which show
atRA significantly increasing water loss, suggesting a decrease in barrier function (Figure
3.6b). However, our investigation did not find that DX314 had a significant effect on
TEWL, nor did it show DX314 mitigating the increase in TEWL by atRA. Because water
transport across the epidermis is a complicated process, it is possible that changes in TEWL
are partially mediated by water transporters such as aquaporins (AQP), rather than a direct
reflection of overall barrier integrity. To see if this may be a possibility, we reviewed our
previously obtained RNAseq data of healthy RHE. We found three water transporters
(AQP3/5/9) were significantly affected by at least one treatment group (Figure 3.9).
Notably, we see that all three aquaporins show decreased gene expression in the high dose
atRA group, AQP3 expression slightly, but significantly, increased in the DX314 group,
and AQP3 and AQP5 increased in the DX314 with atRA cotreatment RHE. Since altered
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expression of AQPs have been correlated with altered TEWL154,155, a decrease in AQP
expression, as seen in high-dose atRA, may result in decreased in TEWL. Despite this, we
showed high-dose atRA significantly increasing TEWL which suggests high-dose atRA
may disrupt barrier function to a larger extent than the TEWL data alone suggests. More
importantly, an increase in AQP expression, as seen in low dose atRA, and DX314 with,
and without atRA cotreatment, may result in TEWL to increase even if gross barrier
function itself is not significantly compromised. This
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and TEWL of an RHE (Figure 3.6c). This suggests
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expression
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that, in general, when one measure is altered by an FDR ≤ 0.05)
external influence, the other tends to be affected as well.
In summary, these studies of DX314 in diseased keratinocytes show DX314
potentiates the effects of atRA like we previously observed in healthy RHE, however, this
was not always the case. DX314 potentiates atRA in DD RHE and RXLI organotypic rafts.
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In RXLI monolayer cultures, DX314 at higher doses successfully potentiated the effects of
low dose atRA. Finally, LI RHE did show a DX314 potentiating atRA but only in the
expression of certain genes (i.e. CYP26A1, STRA6). Most interestingly, we were able to
successfully replicate the barrier reinforcing effects by DX314 first described in our studies
of healthy RHE. This indicates that DX314 does in fact display possess some sort of barrier
reinforcing property which acts independently of many of the atRA-mediated effects we
describe.
We conclude there exists substantial evidence to warrant further investigation into
the therapeutic potential of DX314, not only in the treatment of retinoid-responsive skin
disorders, but also as a novel therapeutic strategy aimed at protecting a compromised skin
barrier.
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4. CONCLUSIONS AND FUTURE DIRECTIONS
The primary intention of this research is to assess the therapeutic potential of the
novel CYP26B1-selective retinoic acid metabolism blocking agent (RAMBA), DX314
through a series of in vivo studies. As the primary disease targets of these compounds are
keratinization disorders, this was accomplished by characterizing the biological effects of
DX314 in several 2D and 3D cultures of healthy and diseased human keratinocytes. We
compare DX314 to several compounds with known therapeutic efficacy including the
endogenous retinoid, retinoic acid (RA), and the two well-studied RAMBAs liarozole and
talarozole.
Keratinization disorders are a heterogenous family of skin diseases related to
abnormal proliferation and differentiation of epidermal keratinocytes. In this study we
investigate DX314 in two such disorders, Darier’s disease and congenital ichthyosis,
however, it should be noted that retinoids have been studied, and/or clinically used in a
wide gamut of dermatological disorders (psoriasis, acne, etc.), as well as several other
diseases (cancer, neurodegenerative disorders, and more). This wide range of therapeutic
applications for compounds affecting retinoid biopathways may allow DX314 to be applied
in the treatment of a plethora of other diseases.
As previously discussed, there already exist several different treatments which take
advantage of the role retinoids in regulating keratinocyte proliferation and differentiation.
The primary strategy of many of these treatments is the direct activation of the target
biopathways, typically via retinoic acid receptor (RAR) agonism. Both endogenous (e.g.
retinol, retinal, tretinoin) and synthetic (e.g. adapalene, tazarotene, etretinate) retinoids that
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utilize this strategy are commonly used, however they can often result in mild-to-severe
adverse effects. These adverse effects are often exacerbated by the homeostatic
autoregulation mechanisms controlling endogenous retinoids such as metabolic
autoinduction (leading to tolerance), and directly influencing the activity or expression of
factors directly involved in retinoid biopathways.
The second strategy involves indirectly modulating endogenous retinoid activity by
RAMBAs (e.g. liarozole and talarozole) which function by inhibiting RA metabolism. This
strategy aims to address many of the issues surrounding direct-acting retinoids in two
fundamental ways: 1. They negate the autoinduction of RA-metabolizing enzymes by
inhibiting their activity, reducing drug tolerance; 2. Extending endogenous retinoid
activity, without needing high-doses of exogenous retinoids, which greatly reduces the risk
of adverse effects caused by excessive retinoid use.
Liarozole is the most thoroughly studied RAMBA and underwent clinical studies
for skin disorders including ichthyosis and psoriasis, as well as prostate and breast
cancer156. It was found to be quite effective at alleviating patient symptoms in both
ichthyosis (Figure 1.12) and palmoplantar pustular psoriasis 109, however despite advancing
to phase III clinical trials, it has not received FDA approval for clinical use, likely due to
its lack of CYP26 specificity (inhibitor of steroid biosynthesis, as well as several CYPs) 157.
Relative to liarozole, talarozole is a significantly more potent CYP26 inhibitor, and showed
similar promise in the treatment of several skin diseases, however, it too has not proceeded
past clinical trials.
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Because the first-generation RAMBAs have not been approved for medical use in
the US, there remains a need for a highly specific, efficacious treatment alternative that
addresses the problems associated with direct retinoid therapy. This lead Diaz et al. to begin
developing a library of compounds aimed at specific inhibition of CYP26-mediated RA
metabolism, with minimal undesirable non-specific effects. These compounds were
designed around the notion that the azole moiety in previous RAMBAs likely contributed
to their off-target activity by interacting with the heme found in other CYPs, as well as
other endogenous enzymes. The compounds designed by Diaz et al. do not contain an azole
group, but still function as CYP26-inhibitors. Early pilot studies identified DX314, among
other compounds, as promising leads for further study which led us to run the studies
presented in this dissertation.
Altogether, these studies conclusively show DX314 successfully potentiates the
effects of atRA in in vitro models of healthy, Darier’s disease, and ichthyotic epidermis,
while showing minimal evidence of undesirable off-target activity. Since the primary
biological activity of retinoids is related to its nuclear receptor-mediated effects of gene
expression, we investigated the gene expression changes of treatments using RT-qPCR and
RNA sequencing studies. Several independent experiments comparing the effects of atRA
and RAMBAs with, and without, low-dose atRA confirmed DX314’s ability to potentiate
the effects of atRA on gene expression in a similar manner to well-studied RAMBAs, with
minimal observations of expression changes indicating off-target activity (Figure 2.2,
Figure 2.5, Figure 2.10, Figure 3.1, Figure 3.3, Figure 3.4). Pathway and upstream regulator
analysis were also done on the RNAseq study results (Figure 2.11). The most activated
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upstream regulator was tretinoin (i.e. atRA) which was predicted to be moderately
activated by low-dose atRA, highly activated by high-dose atRA, not activated by DX314
alone, and very highly activated by DX314 cotreated with low-dose atRA. This analysis
very strongly supports our hypothesis that DX314 potentiates the effects of atRA, without
independently acting on RA pathways. Very weak, or in most cases no activity, was
predicted on the top 20 pathways and upstream regulators identified by DX314 alone which
also support that DX314 does not have significant off-target activity in the absence of RA.
DX314 also showed a potentiating effect on low-dose atRA in 75% of the pathways and
regulators presented also showing strong support of our hypothesis.
To corroborate the observed gene expression changes, we performed histological
immunodetection on several respective proteins. Generally, these data show agreement
with the expected changes based on gene expression effects (Figure 2.3, Figure 3.2). We
did see paradoxical results in CYP26A1 and CYP26B1 immunodetection, which did not
appear to be consistent with the mRNA expression changes (Figure 2.4). However, as
previously discussed, this inconsistency in the relationship between CYP26 mRNA and
protein expression in the epidermis has been previously documented 111,138,139. Although
this effect has not yet been thoroughly investigated, it has been suggested that RA may
induce a post-transcriptional mechanism, perhaps by microRNAs, which could influence
the subsequent translation of CYP26 and resolve this apparent paradox.
One unexpected, but intriguing discovery in this study is the effect DX314 appears
to have on RHE barrier function. The initial observation of this effect was discovered upon
analysis treatment-mediated changes on transepithelial electrical resistance (TEER). TEER
96

informs us of the resistance to ion flow across the tissue, primarily mediated by SG tight
junctions and the occlusive properties of the SC, which functions as a quantifiable measure
of barrier integrity. We found that when treated alone, DX314 at the highest dose given
(1000nM) significantly increases RHE TEER relative to control (Figure 2.6). This contrasts
with the decrease in TEER by atRA, and no change in TEER by liarozole and talarozole.
Additionally, liarozole and talarozole both potentiated the barrier disrupting effects of
atRA, while DX314 appeared to protect the RHE from the expected atRA-induced
decrease in TEER.
Histological analysis reveals the significant effect of atRA on epidermal
morphology including, but not limited to, a significant depletion of the SG which plays a
major role in barrier function (Figure 2.8, Figure 2.9, Figure 3.2). We saw very little effect
on epidermal morphology when liarozole or talarozole were used alone, and an effect
mimicking high-dose atRA when cotreated with low-dose atRA. DX314 on the other hand,
saw minimal depletion of the SG when cotreated with atRA which is consistent with the
observed effect on TEER. Immunodetection of the keratin aggregating protein filaggrin,
which is found in the SG/SC and plays a significant role in epidermal barrier integrity, was
increased by DX314 in DD RHE (Figure 3.2). In contrast, FLG staining was greatly
reduced in atRA treated RHE, and talarozole treated RHE showed no significant change.
Unfortunately, we were not able to replicate this effect on TEER in healthy RHE
due to instrument limitations, and attempts to observe significant changes in another
measure of barrier function, transepithelial water loss (TEWL), were not successful (Figure
2.7). However, the recent investigation of DX314’s effect in LI RHE did replicate this
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increase in TEER (Figure 3.6) suggesting this barrier reinforcing effect applies to diseased
epidermis as well. Despite certain issues, we believe the combination of the healthy and LI
TEER studies, the RHE histology and immunodetection of barrier components, as well as
the observation that many cornified envelope precursor family genes of the EDC were not
affected by DX314 with atRA, but were with atRA alone (Figure 2.10), show compelling
evidence that DX314 has a protective effect on the barrier function of RHE. Since many
skin disorders present with a compromised skin barrier, this discovery, which is clearly not
mediated by a potentiation of atRA, may in fact be a desirable non-specific effect of
DX314. Although we do not identify, or attempt to elucidate, an explanatory mechanism
in these studies, further investigation into this should be performed. If the mechanism
protecting barrier function can be identified, it may lead to a completely novel class of
dermatological drugs aimed at restoring a compromised skin barrier.
We currently have several studies underway which will expand upon the findings
of these studies and prepare for the FDA investigative new drug (IND) application we hope
to submit. Although we did not see any significant evidence of undesirable off-target
activity by DX314, we have performed a small experiment showing that DX314 does not
seem to directly activate RARs. We measured the expression of three, RARE-promoted
(directly modulated by RAR) genes (STRA6, RBP1, TGM2), and one indirectly RAregulated gene (HBEGF), in several treatment combinations of atRA, DX314, and the panRAR antagonist BMS493 (Supplemental Figure 4). We confirmed that atRA modulates
the expression of these RARE-promoted genes, DX314 does not have any effect alone, but
potentiates the effect of low-dose atRA, and BMS493 antagonizes these effects indicating
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they are likely RAR-mediated. We are currently running a large nuclear receptor functional
assay panel to determine if DX314 displays any activity on these receptors. A lack of
significant effect by DX314 on these receptors would provide additional evidence that its
effect is specific to inhibition of CYP26-mediated RA metabolism. Initial results for this
study show that DX314 has no activity on RAR (α, β and γ), PPAR (α, δ and γ), or LXRβ,
and can be found in supplemental data (Supplemental Figure 5).
Another major study we are currently running includes the first in vivo investigation
of topical DX314. This study utilizes the Rhino mouse model which involves a strain of
hairless mouse commonly used in the evaluation of retinoid activity on the skin 158–160. The
skin of the Rhino mouse contains keratinized structures (horn-filled utriculi) and dermal
cysts which are reduced by retinoid treatment. The magnitude of this reduction can be used
to assess a treatment’s potential to correct dyskeratosis in keratinization disorders.
Additionally, the study will investigate DX314’s in vivo effect on TEWL to assess any
changes in barrier function. This study will provide a significant leap in DX314 research
by providing an in vivo study of the compound which will provide even greater therapeutic
relevance.
Moving forward, we will also be running in-depth drug safety assessments,
developing and testing possible topical formulations, and characterizing the
pharmacokinetic profile of DX314 as we aim to move into towards clinical trials, and
ultimately, approval of this promising therapeutic.
Altogether, we conclude the studies performed in this dissertation provide a
compelling basis for further IND-enabling studies and development of DX314 as a novel
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therapy in keratinization disorders. We also show DX314 may have therapeutic relevance
in the treatment of Darier’s disease, a disorder in which RAMBAs have not been studied
in the past. Additional studies currently underway will provide significant insight into the
translational application of this compound and reinforce the body of promising evidence
suggesting DX314’s therapeutic potential. Finally, evidence showing DX314 may
reinforce skin barrier function and protect from some undesirable effects of retinoid
therapy, may provide a completely novel strategy for restoring and protecting a
compromised skin barrier. It is our hope that work done here will lead to significant
improvements in the quality of life and outcomes of patients suffering from various
dermatological disorders.
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6. APPENDICES
6.1 SUPPLEMENTAL DATA
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Supplemental Figure 1: Integrin signaling pathways. IPA predicted activity of canonical pathway components based on
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Supplemental Figure 2: RhoDGI Signaling Pathway. IPA predicted activity of canonical pathway
components based on differential expression analysis by RNAseq: (a) 1nM atRA, (b) 100nM atRA,
(c) 1000nM DX314, (d) 1000nM DX314 + 1nM atRA. Values below each molecule shows respective
fold-change in RNA expression from control.
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Supplemental Figure 3: RAR Activation Pathway. IPA predicted activity of
canonical pathway components based on differential expression analysis by
RNAseq: (a) 1nM atRA, (b) 100nM atRA, (c) 1000nM DX314, (d) 1000nM
DX314 + 1nM atRA. Values below each molecule shows respective fold-change
in RNA expression from control.
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Supplemental Figure 4: Effect of pan-RAR antagonist BMS493 on gene
expression effects by atRA, RAMBAs. Effects of candidate RAMBAs DX314
(left column) or DX308 (right column) with, or without, low dose atRA, on
HBEGF, and RARE-promoted (STRA6, TGM2, RBP1) gene expression compared
to atRA. All treatments are also done in the presence, or absence, of pan-RAR
antagonist BMS493. This study was performed in autocrine monolayer cultures of
healthy keratinocytes. Bars show mean ± 95% CI.
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Supplemental Figure 5: Nuclear Receptor EC50 Screening
of DX314, DX308. Performed by Syneos Health using HeLa
lec2P/9XGAL4 cell lines transfected with expression vector
for respective nuclear receptor. IA = Inactive.
Note: This data shows the preliminary data of an ongoing study
and may not represent the final study results.
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